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ABSTRACT 
B-cell Non-Hodgkin Lymphomas (B-NHL) are a heterogeneous group of cancers, broadly 
diffused worldwide and often relapsing after standard treatment and rituximab. Therapeutic 
vaccines targeting B-NHL idiotype (Id) represent a promising approach to maintain the 
complete response induced by standard treatments. However, customized idiotypic vaccination 
still remains a non-approved, experimental therapeutic option, mostly due to the personalized 
use and penalized by the lack of reliable clinical or biological markers of patient eligibility and 
responsiveness. Nevertheless, the molecular characterization of different lymphoid tumor 
histotypes revealed a set of stereotyped immunoglobulins among distinct B-cell lymphoma 
types. On this ground, we focused our attention on the IGHV1-69 protein, frequently expressed 
in HCV-associated lymphomas, chronic lymphocytic leukaemia, and auto-immunity related 
lymphoproliferations, and we characterized the ex vivo immunogenicity of this protein. 
Seventy IGHV1-69 sequences obtained from patients affected by different B-NHLs or 
pre-malignant lymphoproliferations were compared to design an optimized sequence 
characterized by the highest degree of similarity among studied cancers, and thus CDR3 
hypervariable region free. Within this “immunogenically” optimized sequence, we identified 13 
potential HLA class-I cytotoxic T lymphocyte (CTL) epitopes and synthesized the corresponding 
pentamers (Pent). We assessed by flow cytometry the presence and extent of epitope-specific 
T-cell responses in peripheral blood of patients with IGHV1-69
+
 B-cell lymphoproliferative 
disorders and healthy donors, and validated these data in IFN-γ ELISPOT (Enzyme-linked 
immunosorbent spot) assays. Finally, we boosted in vitro IGHV1-69-specific responses by 
stimulating peripheral blood lymphocytes (PBL) from donors and patients with different 
protocols for the generation of epitope-specific CTL cultures.  
Interestingly, the IGHV1-69 Pent
+
 population observed in patients’ samples was 
generally larger than in donors, supporting the existence of spontaneous memory T-cell 
responses against IGHV1-69, at least for some HLA-restrictions. Surprisingly, in patients’ 
samples, IGHV1-69-recognizing T cells displayed higher IFN-γ release in ELISPOT assays 
compared to viral-specific T cells. Moreover, we obtained peptide-specific CTL lines, which 
showed a weak but specific lysis against peptide-pulsed targets, especially when derived from 
patients’ PBLs. In addition, we were able to generate IGHV1-69-epitope specific CTL clones from 
healthy donors CD8
+
 T cells, employing synthetic artificial APC, developed to elicit and expand 
low-avidity tumor-directed human CTL lines. Finally, IGHV1-69-induced CTL lines showed 
specific lysis also towards an IGHV1-69 naturally expressing cell line, suggesting that IGHV1-69 
memory T-cell responses could be boosted for therapeutic purposes. 
 These results show that IGHV1-69 constitutes a potential target for the development of 
a subset-specific Id vaccine. Furthermore, multimer (tetramers and pentamers) and ELISPOT 
immune-monitoring may partially overcome the main limitations of current Id-targeting 
vaccinations and further improve their clinical efficacy. 
 
Abstract (Italian) 
I Linfomi Non-Hodgkin a cellule-B (B-NHL) rappresentano un  gruppo eterogeneo di 
patologie, ampiamente diffuse nel mondo e caratterizzate da frequenti ricadute in seguito a 
trattamenti standard o terapia con rituximab. Vaccini terapeutici che hanno come bersaglio 
l’Idiotipo (Id) dei B-NHL, costituiscono un approccio promettente nel mantenere la risposta 
completa indotta con trattamenti standard. Tuttavia, i vaccini idiotipici personalizzati 
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rappresentano ancora un approccio terapeutico sperimentale e non approvato su larga scala, 
principalmente perché paziente-specifici e perché privi di marcatori attendibili per 
l’identificazione di pazienti elegibili e di risposta alla terapia. Ciononostante, la caratterizzazione 
molecolare di differenti istotipi di tumori di origine linfoide, ha rivelato la presenza di una serie 
di immunoglobuline stereotipate anche fra linfomi di diverso tipo. Su questi presupposti, 
abbiamo focalizzato la nostra attenzione sulla proteina IGHV1-69, frequentemente espressa in 
linfomi associati all’infezione da HCV, nella leucemia linfatica cronica (CLL) e in 
linfoproliferazioni associate ad auto-immunità, e abbiamo valutato in vitro l’immunogenicità di 
questa proteina. 
Inizialmente, abbiamo confrontato 70 sequenze relative alla proteina IGHV1-69 e 
ottenute da pazienti affetti da differenti B-NHLs o linfoproliferazioni pre-maligne, allo scopo di 
ideare una sequenza ottimizzata, caratterizzata dal maggior grado di similarità fra i tumori presi 
in esame, e pertanto priva della regione ipervariabile CDR3. All’interno di questa nuova 
sequenza, abbiamo identificato 13 epitopi potenzialmente riconoscibili da linfociti T citotossici 
(CTLs) nell’ambito di 7 alleli HLA di classe I, e abbiamo sintetizzato i corrispondenti pentameri 
(Pent). Tramite citofluorimetria a flusso abbiamo quindi valutato la presenza di risposte T-
cellulari specifiche per gli epitopi derivati da IGHV1-69, in campioni di sangue periferico 
ottenuti da pazienti affetti da linfoproliferazioni esprimenti IGHV1-69 e da donatori sani. 
Abbiamo inoltre validato questi dati tramite saggi ELISPOT (Enzyme-linked immunosorbent 
spot) per l’identificazione del rilascio di IFN-γ. Infine abbiamo stimolato in vitro le risposte 
specifiche per IGHV1-69, inducendo i linfociti del sangue periferico (PBLs) di donatori sani e 
pazienti, attraverso diversi protocolli per la generazione di colture CTL epitopo-specifiche. 
E’ stato interessante osservare come nei campioni ottenuti da paziente la popolazione di 
linfociti T CD8
+
 positiva ai pentameri specifici per gli epitopi di IGHV1-69 sia risultata 
generalmente più numerosa della corrispondente popolazione osservata in donatori sani. 
Questo dato supporta l’esistenza di risposte memoria T cellulari nei confronti di IGHV1-69, 
almeno in alcune restrizioni HLA. Inoltre, nei campioni ottenuti da paziente le cellule T 
specifiche per gli epitopi di IGHV1-69 hanno rivelato in saggi ELISPOT un maggior rilascio di IFN-
γ rispetto ai linfociti T specifici per epitopi virali. In aggiunta, stimolando parallelamente PBLs di 
donatori sani e pazienti, abbiamo ottenuto linee CTL peptide-specifiche, in grado di riconoscere 
debolmente, ma in modo specifico target caricati con il peptide d’interesse, soprattutto quando 
derivate da PBLs di pazienti. Inoltre, tramite l’utilizzo di antigen-presenting cells artificiali, 
prodotte allo scopo di indurre ed espandere linee CTL caratterizzare da bassa affinità nei 
confronti di antigeni tumorali, abbiamo anche generato cloni CTL specifici per un epitopo di 
IGHV1-69 a partire da linfociti T CD8
+
 di donatori. Infine, si è evidenziato che colture CTLs 
indotte in seguito a stimolo con epitopi derivanti da IGHV1-69, sono in grado di riconoscere in 
modo specifico una linea cellulare naturalmente esprimente IGHV1-69, suggerendo in questo 
modo che le risposte memoria T-cellulari specifiche per IGHV1-69, possano essere stimolate ed 
espanse a scopi terapeutici. 
Questi risultati dimostrano che IGHV1-69 costituisce un target potenziale per lo sviluppo 
di un vaccino Id applicabile su un sottogruppo di linfomi a cellule B. Inoltre, 
l’immunomonitoraggio tramite marcatura con multimeri (tetrameri o pentameri) e saggi 
ELISPOT potrebbe eludere almeno parzialmente i principali limiti degli attuali vaccini idiotipici, 
al fine di incrementare ulteriormente la loro efficacia clinica. 
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INTRODUCTION 
The challenge of anti-tumor vaccination 
In the multidisciplinary treatment of cancer patients, therapeutic vaccines represent one 
of the most fascinating and promising strategies. Compared to standard modalities (chemo- 
and radiotherapy, surgery, adaptive immunotherapy), anti-tumor vaccination might have the 
potentiality to persist a lifetime and to induce an effective anti-tumor immune response able to 
cure the established tumor and keep it under constant control, thus prolonging survival [1].  
In contrast to prophylactic vaccines against pathogens, where the target antigens are 
foreign to the immune system, the majority of cancer vaccine (CV) targets are close to self 
antigens and therefore generally less immunogenic. However, in the last decades, the 
identification of tumor-associated antigens (TAA) from human malignancies and the discovery 
that tumors can be recognised by the immune system, stimulated a broad array of 
immunological strategies for the successful generation of CVs [2]. Vaccines can be developed 
against a specific target, such as peptide- or protein-based approaches, or they can be less well 
defined as whole-tumor cell lysates. In this context, several molecular and cell biology 
platforms have been produced including engineered DNA plasmids or recombinant viral 
vectors, and dendritic cell-based vaccines, in order to stimulate B cells, T cells, or professional 
antigen presenting cells (APCs) (Figure 1). These reagents are expected to exert antitumor 
effects by engaging the host immune response, and have great potential for circumventing the 
intrinsic drug resistance that limits standard cancer management [2].  
 
Figure 1. Molecular and cell biology-based cancer vaccine platforms. Examples of current vaccinations are reported 
in each platform [2]. 
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The quest for the appropriate target 
The main intent of therapeutic CVs is to “train” the patient’s own immune system to 
specifically recognize and eliminate tumor cells. To this issue, the target selection becomes 
pivotal. The potential target for the immune response can be either an antigen expressed only 
on tumor cells (Tumor-Specific Antigen, TSA), or an antigen present mostly on tumor cells but 
also shared by some normal cells (TAA). TSAs would be the ideal target for immunotherapy 
because of their specificity and their frequent involvement in tumorigenesis and cancer 
progression. However, most of the mutations that identify TSAs are unique to each tumor, and 
thus required the development of personalized treatments. Conversely, TAAs are shared among 
tumors with the same histology and also of different origin, but they are limited by their weak 
immunogenicity due to the tolerance for self antigens acquired during the development of the 
immune system. Therefore, the most promising TAAs should be broadly expressed among 
different tumor types, and play a central role in the oncogenic process, to overcome immune 
escape by mutation or loss of antigen by tumor cells [1].  
The validity of a vaccine target depends also on several issues, as the ability of tumor 
cells to present it in the context of MHC for T- and B-cell recognition, the level of expression, 
the relative specificity for tumor in comparison to normal tissue, and on the degree of tolerance 
to the given TAA [3]. The spectrum of current and potential therapeutic CV targets includes 
different classes of TAA: oncoproteins characterized by somatic point mutations that helps to 
drive the neoplastic process, as for example mutant RAS in colon and pancreatic cancer, or 
overexpressed oncoproteins such ad HER2/neu and the carboxy terminus of MUC-1; oncofetal 
antigens like the carcinoembryonic antigen (CEA) and underglycosylated MUC-1, and cancer-
testis antigens such as melanoma-associated antigens (MAGE); “tissue-lineage” proteins, 
overexpressed in tumors as the melanoma-associated antigens glycoprotein 100 (gp100) and 
the tyrosinase, and normally expressed in a non-vital organ, like prostate-specific antigen (PSA); 
molecules associated with cancer “stem cells” and/or the epithelial–mesenchymal transition 
(EMT) process; and viral proteins [3]. Nevertheless, most of these antigens derive from self-
proteins, which may induce immune tolerance. On the other hand, the mutation or 
modification of self-antigens entails the development of immunogenic TAA.  This aspect 
represents a challenge for the appropriate design of vaccines that have to overcome the 
immune tolerance in order to elicit specific antitumor immunity without autoimmune side 
effects. The induction of this specific immune response may cause the selection and expansion 
of tumor variants, which lack the target tumor antigen and become resistant to the vaccine-
induced immune response. Otherwise, such tumor variants may induce a beneficial effect, 
broadening the immune response against newly expressed antigens not present in the original 
vaccine in a process defined as “epitope spreading” [4]. 
The strategy to identify suitable TAAs is relatively easier in hematological disease if 
compared to solid tumors. Lymphomas originated from B cells, in fact, are characterized by the 
expression of the immunoglobulin Idiotype (Id), which characterizes the B-cell receptor (BCR) of 
every single B lymphocyte, and is maintained by the tumor clone during the tumorigenesis 
process. For these reasons, sequence analysis for the identification of cancer-related mutations 
can be focused on the immunoglobulin Id, which can be used for the development of a patient-
specific vaccine [4]. 
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Selection of patients and clinical trial response endpoints 
Recent studies revealed two major issues in the optimal design of clinical trials testing 
the efficacy of CVs: the selection of a suitable patient population and the choice of the most 
appropriate clinical trial endpoints [3]. Generally, phase I and some phase II clinical trials are 
performed on patients with advanced disease and after administration of multiple 
chemotherapy regimens, thus with severe immune-impairment [2]. In heavy tumor-burden 
patients, the ability of vaccines to generate anti-tumor immune response is strongly limited by 
numerous tumor-produced immunosuppressive factors (eg, transforming growth factor-β and 
vascular endothelial growth factor) and immunoregulatory mechanisms (eg, regulatory T cells 
[Tregs] and myeloid derived suppressor cells) [5]. Consequently, patients with large tumor 
burdens would be even less likely to respond to vaccines than to chemotherapy [3]. 
Conversely, there are several examples of greater vaccine efficacy in patients with low-
grade or indolent disease, and in individuals who have received fewer regimens of 
chemotherapy with a longer time since their last chemotherapy [3]. Thus, the main limitations 
observed in the first clinical trials can be overcome by testing CVs in the setting of minimal 
residual disease or in patients with complete remission after primary treatment [2]. 
Moreover, the optimal clinical trial setting for testing a novel therapeutic CV formulation 
may not fit the traditional model developed for chemotherapy drug trials, and one may need to 
select different endpoints such as molecular remission rate and time to progression, rather 
than response rates [6]. Immune responses often take time to develop and can be potentially 
enhanced by continued booster vaccination, thus vaccines have the potentiality to apply 
antitumor activity for a long time, resulting in a slower tumor growth rate. This process may 
continue for months or years and through subsequent therapies, leading to improved overall 
survival (OS), but maybe with low rate of objective response [3]. 
Therefore, early clinical trials with vaccines may have been terminated prematurely 
when tumor progression occurred, often before a sufficient number of vaccine boosts could 
have been administered. This phenomenon has led to the quest of a new design for CV trials 
and to the identification of more suitable immune response criteria [3]. 
Advantages and drawbacks of current cancer vaccines 
The therapeutic approach of CVs has several advantages if compared with conventional 
anti-cancer treatments, especially if toxicity is considered. Differently to chemotherapy, 
therapeutic vaccination has the potential ability to circumvent drug cross-resistance and to 
induce a persistent antitumor effect due to immunologic memory, thus reducing side effects. 
Moreover, the development of therapies specifically targeting TAAs has the advantage to direct 
the immune response mainly against tumor cells and only few other normal tissues [7-9]. 
Unfortunately, despite the promising results coming from pre-clinical models, the first 
clinical data about CVs were quite disappointing. Several reasons may explain the limited 
clinical success of anti-tumor vaccination, including the trial design, the specific vaccination 
approach and host-related factors [2]. One of the main limitations is due to the impaired 
interplay between tumor and host immune system, which involves the selection of highly 
aggressive transformed cells that no longer express cancer-specific molecules, the induction of 
immune tolerance mechanisms (for example the down-regulation of the antigen-processing 
machinery, the production of immunosuppressive cytokines, the lack of co-stimulatory 
molecules) and the recruitment of tolerizing dendritic cells and Tregs, which negatively contrast 
the immune response [2]. 
One of the main drawbacks of CVs is also the functional dissociation between systemic 
and local immune responses. This is mainly linked to the lack of reliable immunologic surrogate 
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markers of clinical response. Antibody production has been reported to correlate with clinical 
outcome only in some cases [7,8], while findings regarding the diagnostic significance of T-cell 
responses are conflicting. Some papers claimed indeed that no currently available in vitro 
assays can accurately mirror the in vivo antitumor activity of T-cells [2], whilst others were able 
to show a clear correlation between clinical outcome and tumor-specific T-cell responses in the 
peripheral blood [10-13]. 
Presently, CVs can probably have an important role as adjuvant to traditional therapies 
in the management of minimal residual disease, in particular for patients who are at high risk to 
relapse [2]. In this context, a recent randomized phase III study reported by Schuster et al [14] 
suggests that it would be possible to identify a subgroup of patients with follicular lymphoma in 
first remission after standard treatment, who may benefit from receiving an anti-Id vaccination 
[15].  
The current management for B-cell Non-Hodgkin Lymphomas 
Non-Hodgkin Lymphomas: a heterogeneous group of cancers 
Lymphomas are a heterogeneous group of solid tumors of the immune system. 
Hodgkin’s lymphomas account about 10% of lymphomas, while the remaining 90% are referred 
to as Non-Hodgkin’s lymphomas (NHLs). NHLs have a wide range of histological appearances 
and clinical features at presentation, 85-90% arise from B lymphocytes, the remainder 
originates from T cells or natural killer (NK) cells. This diverse group of malignancies usually 
develops in the lymph nodes, but can occur in almost any tissue, and ranges from the more 
indolent follicular lymphoma, to the more aggressive diffuse large B-cell and Burkitt’s 
lymphomas. Several different classification systems have been proposed to group these 
malignancies according to their histological characteristics [16]. The firt Rappaport (1966) and 
Working Formulation (WF, 1982) classifications were based on histological characteristics, with 
the Kiel system (1988) the T/B-cell origin was introduced in the classification parameters, and 
finally the REAL (Real European American Classification of Lymphoid Neoplasm, 1994) and the 
most recent WHO classification (2008) takes account also phenotypic, clinical and genetic 
features
1
. The following list shows the WHO classification of mature B-cell NHL (B-NHL) in force 
since 2008 [17]: 
Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma 
B-cell prolymphocytic leukemia 
Splenic marginal zone lymphoma (SMZL) 
Hairy cell leukemia 
Splenic lymphoma/leukemia, unclassifiable 
 Splenic diffuse red pulp small B-cell lymphoma 
 Hairy cell leukemia-variant 
Lymphoplasmacytic lymphoma 
 Waldenström macroglobulinemia 
Heavy chain diseases 
 Alpha heavy chain disease 
 Gamma heavy chain disease 
 Mu heavy chain disease 
Plasma cell myeloma 
Solitary plasmacytoma of bone 
Extraosseous plasmacytoma 
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) 
                                                     
1
http://www.cancer-amcc.org/FICHIERS/files/Principles%20of%20WHO%20Classification%20for%20Lymphomas.pdf 
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Nodal marginal zone B-cell lymphoma (MZL) 
 Pediatric type nodal MZL 
Follicular lymphoma (FL) 
 Pediatric type follicular lymphoma 
Primary cutaneous follicle center lymphoma 
Mantle cell lymphoma (MCL) 
Diffuse large B-cell lymphoma (DLBCL), not otherwise specified 
 T cell/histiocyte rich large B-cell lymphoma 
 DLBCL associated with chronic inflammation 
 Epstein-Barr virus (EBV)+ DLBCL of the elderly 
Lymphomatoid granulomatosis 
Primary mediastinal (thymic) large B-cell lymphoma 
Intravascular large B-cell lymphoma 
Primary cutaneous DLBCL, leg type 
ALK+ large B-cell lymphoma 
Plasmablastic lymphoma 
Primary effusion lymphoma 
Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease 
Burkitt lymphoma 
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and 
Burkitt lymphoma 
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and 
classical Hodgkin lymphoma  
Since the various types of B-cell lymphoma can have different clinical behaviors, and 
thus require diverse treatment strategies, another classification (based on the previous REAL 
system) was proposed for lymphoproliferative disorders according to whether they belong to 
the indolent (slow growing) or aggressive subtype. This system includes also T- and NK-cell 
lymphomas, as well as Hodgkin’s diseases [18]
2
: 
Indolent lymphoma/leukemia 
A. Follicular lymphoma (follicular small cleaved cell [grade 1], follicular mixed small cleaved and large cell 
[grade 2], diffuse small cleaved cell) 
B. Chronic lymphocytic leukemia/small lymphocytic lymphoma 
C. Lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia) 
D. Extranodal marginal zone B-cell lymphoma (MALT lymphoma) 
E. Nodal marginal zone B-cell lymphoma (monocytoid B-cell lymphoma) 
F. Splenic marginal zone lymphoma (splenic lymphoma with villous lymphocytes) 
G. Hairy cell leukemia 
H. Mycosis fungoides/Sezary syndrome 
I. T-cell granular lymphocytic leukemia 
J. Primary cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis (CD30+) 
K. Nodular lymphocyte predominant Hodgkin's lymphoma   
 
Aggressive lymphoma/leukemia 
A. Diffuse large cell lymphoma (includes diffuse mixed cell, diffuse large cell, immunoblastic, T-cell rich 
large B-cell lymphoma) Distinguish: 
 1. Mediastinal large B-cell lymphoma 
 2. Follicular large cell lymphoma (grade 3) 
 3. Anaplastic large cell lymphoma (CD30+) 
 4. Extranodal NK/T-cell lymphoma, nasal type 
 5. Lymphomatoid granulomatosis (angiocentric pulmonary B-cell lymphoma) 
 6. Angioimmunoblastic T-cell lymphoma 
 7. Peripheral T-cell lymphoma, unspecified 
 8. Subcutaneous panniculitis-like T-cell lymphoma 
 9. Hepatosplenic T-cell lymphoma 
                                                     
2
 (http://www.nhlcyberfamily.org/classification.htm) 
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 10. Enteropathy-type T-cell lymphoma 
 11. Intravascular large B-cell lymphoma 
B. Burkitt lymphoma/Burkitt cell leukaemia/Burkitt-like lymphoma 
C. Precursor B- or T-cell lymphoblastic lymphoma/leukaemia 
D. Primary CNS lymphoma 
E. Adult T-cell leukaemia/lymphoma (HTLV 1+) 
F. Mantle cell lymphoma 
G. Polymorphic post-transplantation lymphoproliferative disorder (PTLD) 
H. AIDS-related lymphoma 
I. True histiocytic lymphoma 
J. Primary effusion lymphoma 
K. Aggressive NK-cell leukemia/blastic NK-cell lymphoma 
L. B- or T-cell prolymphocytic leukemia  
The annual incidence of B-NHL is about 12 cases in 100,000 inhabitants in Western 
Europe [19]. In 2007, around 65,540 people were diagnosed with NHL in the USA, and about 
20,210 people died of the disease in 2008 [20]. NHL is the fifth most frequently diagnosed 
cancer in the UK, and more than two-thirds of patients are 60 years and older. The male age-
standardized incidence per 100,000 men (17.7) is higher than the female incidence (12.8), while 
the frequency of specific subtypes of lymphoma varies substantially by geographic region. For 
example, adult T-cell lymphoma associated with infection by human T-cell lymphotropic virus 
type 1 (HTLV-1) is much more frequent in east Asia than in other regions, as is nasal NK-cell or 
T-cell lymphoma associated with Epstein-Barr virus infection, whereas follicular lymphomas are 
more frequent in western Europe and North America. Diffuse large B-cell lymphoma, by 
contrast, is common worldwide [16]. The annual mortality from B-NHL ranges around 5 in 
100,000 inhabitants, but the individual probability of survival is highly determined by the 
histological subtype, age, clinical stage and additional risk factors [19]. 
Several causes have been linked with the etiology of B-NHLs, the most established risk 
factor is immunosuppression. Indeed, an increased risk to develop high-grade NHL is observed 
in patients with human immunodeficiency virus (HIV), organ-transplant recipients, patients who 
have had high-dose chemotherapy with stem-cell transplantation, and those with inherited 
immunodeficiency syndromes or autoimmune disease. Different infectious agents have been 
associated with lymphoma development, either by inhibition of the immune function, or by 
induction of a chronic inflammatory response [16,18]. The Epstein-Barr virus (EBV) for example 
plays a role in Burkitt’s lymphoma etiology [21], another member of the herpes-virus family, 
human herpes virus 8 (HHV8), is implicated in the pathogenesis of primary effusion lymphomas 
[22], while Helicobacter pylori is a risk factor for gastric MALT lymphomas [23], hepatitis C virus 
(HCV) has been associated with splenic marginal zone lymphoma [24], Borrelia burgdorferi has 
been found in cutaneous MALT [25], and Chlamydophila psittaci infection is involved in ocular 
adnexal lymphomagenesis [26]. Other than pathogen-derived antigens that cause chronic 
infections, certain autoantigens can also stimulate reactive B cells. This concept is also 
supported by the observation that several autoimmune diseases, such as Sjogren’s syndrome, 
rheumatoid arthritis and autoimmune lymphoproliferative syndrome are commonly associated 
with an increased risk of lymphoma [18]. Moreover, studies in different lymphoma types (B-
CLL, follicular lymphoma, MALT lymphomas) indicated that lymphoma cells are able to 
recognize autoantigens or foreign antigens, and that stimulation by antigen binding contributes 
to survival and proliferation of lymphoma cells [18]. Recently, the characterization of several 
subgroups of B-CLL revealed the expression of strikingly similar VH and VL gene-rearrangement 
sequences among members of the same group [27-31], reflecting the selection and activation 
of these cases by a restricted set of antigenic epitopes [18]. 
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Reciprocal translocation involving one of the immunoglobulin gene and a proto-
oncogene are a hallmark of many types of B-cell lymphomas. This translocation leads to a 
deregulated, constitutive expression of the oncogene. Somatic hypermutation and class-switch 
recombination may be the molecular processes mainly involved in chromosomal translocation. 
Both of them occur mainly in the germinal center (GC), and probably it is for this reason that 
most of B-cell lymphomas derive from GC B-cells or their descendents (Figure 2). Moreover, 
these processes do not occur in the DNA of T-cells, which could also partly explain why B cells 
are more prone to undergo malignant transformation than T cells [18].  
 
Figure 2. Cellular origin of B-cell lymphomas [18]. 
It is well known that BCR supplies important survival signals to normal B cells and recent 
observations support this BCR critical role also in lymphoma B cells. Treatment of patients with 
follicular lymphoma with anti-Id antibodies did not result in the emergence of BCR-negative 
lymphoma variants [32], demonstrating the pivotal role of BCR in cancer cell survival [18]. 
Moreover, immunoglobulin loss variants have rarely been described and only in certain B-NHL, 
such as follicular lymphoma [6]. 
The most widely used prognostic model for patients with B-NHL is the International 
Prognostic Index (IPI), which delineate four risk groups considering independent clinical 
features such as age (≤60 years vs>60 years), lactate dehydrogenase concentration (normal vs. 
abnormal), Eastern Cooperative Oncology Group performance status (<2 vs ≥2), Ann Arbor 
stage (I/II vs. III/IV), and number of extranodal sites implicated (≤one vs. >one). The groups are 
identified with the number of unfavorable clinical features involved: low risk (zero to one 
clinical feature), low-intermediate risk (two features), high-intermediate risk (three features), 
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and high risk (four to five features) [16]. The IPI together with the WHO classification and the 
aggressive subtypes are all relevant for the choice of the most suitable therapeutic strategy. 
Therapeutic approaches 
Standard treatments 
Over the years, several randomized trials compared the efficacy of different 
combinations of standard chemo- and radio-therapy in distinct lymphoma histotypes [16]. The 
purine analogues cladribine and, particularly, fludarabine have activity against small B-cell 
lymphocytic lymphoma and chronic lymphocytic leukaemia [33]. Bendamustine is a native first-
line treatment option for patients for whom fludarabine containing regimens are not 
appropriate.  
Conversely, FL is not usually curable with conventional treatment. The exception is the 
few patients with limited-stage disease, who can be cured with radiotherapy, a few patients 
with exceptional responses to initial chemotherapy regimens, and some patients after 
autologous or allogeneic haemopoietic stem-cell transplantation as second-line therapy. Other 
treatment regimens include oral chlorambucil, fludarabine, or bendamustine; or combination 
chemotherapies with cyclophosphamide, vincristine, and prednisolone; or anthracycline-
containing regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and 
prednisone) [34].  
Several studies have assessed the role of high-dose chemotherapy and autologous stem-
cell transplantation in patients with mantle-cell lymphoma. For the rare, young patients with an 
HLA-matched donor, allogeneic haemopoietic stem-cell transplantation can be curative [35]. 
Surgery has proved as the therapeutic choice for localized mucosa-associated lymphoid 
tissue lymphomas at all sites, and in particular for a rare subtype, splenic marginal-zone 
lymphoma, which involves the spleen, blood, and bone marrow. 
In localized diffuse large B-cell lymphoma (25% of patients) findings from trials 
comparing radiation alone with radiation plus combination chemotherapy with 
cyclophosphamide, vincristine, and prednisolone or CHOP, showed an improvement in OS for 
dual modality therapy, which became the standard treatment. However, disseminated disease 
is the most common presentation of diffuse large B-cell lymphoma, and about a third of 
patients with this form of the disease were cured with chemotherapy alone, most by the CHOP 
regimen [36].  
For highly aggressive forms as Burkitt’s lymphoma, principles of chemotherapy delivery 
include maintenance of high dose intensity and the use of alternating non cross-resistant 
regimens to prevent the emergence of drug resistance [16]. 
Nevertheless, conventional chemotherapy yields high remission rates in lymphoma by 
eliminating actively dividing cells, meanwhile a quiescent but lethal subpopulation (i.e., cancer 
stem cells) may be responsible for disease relapse and its incurability with standard therapy [5]. 
The introduction of monoclonal antibodies 
In the management of lymphoma, especially for the indolent forms, new therapeutic 
modalities that target tumor cells more specifically and with less toxicity are needed [37]. In 
this context, the concept of immunotherapy is appealing. Among malignant diseases, 
lymphoma is ideally suited to immunotherapy. Indeed, B-cell lymphomas express either class I 
and II MHC molecules, which enables them to present their own tumor associated antigens to 
both CD8 and CD4 T cells [5]. 
The first developed antibody-based therapy for B-cell lymphoma tested anti-Id 
monoclonal antibodies (mAbs). Although these antibodies were then abandoned because they 
need to be tailored for each patient, they provided evidence that antibody-based therapy can 
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be safe and highly effective [38], paving the way for subsequent development of the anti-CD20 
mAb rituximab [37]. Rituximab (Rituxan, Mabthera) is a chimeric anti-CD20 antibody derived 
from the mouse mAb 2B8, targeting CD20 antigens, following replacement of the heavy and 
light chain constant regions with the corresponding regions of a human IgG1 mAb. It depletes 
both normal and malignant B cells [39]. Four major mechanisms have been proposed for the 
action of rituximab: antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis, 
complement-dependent cytotoxicity (CDC), direct induction of apoptosis, and “vaccination 
effect” resulting from cross-priming. These mechanisms have been demonstrated in vitro and in 
mouse models, and clinical observations support their activity in patients [37]. 
As a single agent or in combination with chemotherapy, rituximab was able to improve 
the overall response rate (ORR), the duration of response and OS in several lymphoma 
subgroups [37]. Findings from one large trial showed an improvement in OS in patients with 
previously untreated CLL given fludarabine, cyclophosphamide, and rituximab compared with 
those given chemotherapy alone [16]. Furthermore, since phase III randomised controlled trials 
have shown improved OS with the addition of this agent to chemotherapy, current guidelines 
for the treatment of FL recommend that rituximab is administered in combination with 
standard chemotherapy in previously untreated stage III–IV FL, and at first relapse, and it is 
recommended as a monotherapy for stage III–IV chemoresistant FL, or at second relapse after 
chemotherapy [16,39,40]. Studies assessing the addition of rituximab to standard 
chemotherapy in mantle cell lymphoma have shown significant improvements in complete 
response rates and time-to-treatment failure, but disappointingly not in OS [16]. Data from the 
Surveillence, Epidemiology, and End Results (SEER) registry comparing survival in all patients 
with Diffuse Large B-Cell Lymphoma (DLBCL) from 1973–2004 show that survival has 
substantially improved since the advent of rituximab [16]. For this reason, rituximab has been 
approved for previously untreated DLBCL patients in combination with CHOP chemotherapy 
and with salvage chemotherapy regimens in relapsed/refractory patients [39]. Moreover, 
several studies are assessing the role of rituximab as part of high-dose regimens (HDT) pre-
autologous stem cell transplantation (ASCT) in young high-risk patients with DLBCL achieving a 
complete remission after a complete course of chemotherapy [39]. 
Some new generation mAbs are currently undergoing clinical investigation. In particular, 
humanized anti-CD20 mAbs have been produced with the aim to enhance rituximab 
mechanism of action and reduce resistance phenomenon. Among them, one of the most 
promising candidates is the fully human type I Ofatunumab. The monotherapy with this mAb 
seems to be ineffective in rituximab-refractory FL; however, studies of ofatumumab combined 
with CHOP chemotherapy in patients with FL are ongoing [37]. The mAb appears to be more 
effective in CLL than in FL, as demonstrated by the FDA approval and conditional approval in 
Europe for the treatment of refractory CLL [16]. Some other examples of new-generation mAbs 
include Epratuzumab, a humanized IgG1 anti-CD22 antibody, which induced objective response 
in relapsed FL and DLBCL; Galiximab, a primatised anti-CD80 (IgG1λ) mAb able to enhance 
rituximab antitumor activity in previously untreated NLH patients, with a response reported in 
70% of patients; Alemtuzumab, a humanized monoclonal antibody against CD52, indicated for 
the treatment of patients with B-CLL refractory to fludarabine, and for advanced-stage mycosis 
fungoides/Sezary syndrome; Apolizumab, a humanized anti-HLA-DR antibody, used in 
combination with rituximab in relapsed B-CLL [39] (Figure 3). 
Finally, to further exploit the ability of mAbs to reach the tumor site, 
radioimmunotherapy has been developed linking a radioisotope to the antibody. This approach 
permits the targeting of the radioactive isotopes to cancer tissues and is especially interesting 
as it allows for killing neighboring cancer cells that either are inaccessible to the antibody or 
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express insufficient antigen for the antibody to bind in adequate quantities. Two anti-CD20 
radioimmunoconjugates are approved for use in patients with relapsed or refractory follicular 
or low-grade lymphoma: Yttrium-90-labelled ibritumomab tiuxetan (zevalin), and iodine-131-
labelled tositumomab (bexxar) [16,37,39] (Figure 3). 
 
Figure 3. Monoclonal antibodies (and therapeutic targets) employed in the current management of B-NHL 
(modified by [16]). 
Treatment of recurrences and relapses 
Efforts to improve rituximab and other mAbs efficacy induced a general enhancement of 
remission and OS in B-NHL patients, but eventually patients still relapse from residual tumor 
cells and die of the disease [37]. Indeed, patients usually respond well to the first-line of 
rituximab and chemotherapy induction, but typically experience repeated relapses and 
shortening of the time from treatment to treatment [41]. Current guidelines recommend the 
use of rituximab as a maintenance therapy only in relapsed or refractory FL responding to 
induction therapy with chemotherapy with or without rituximab [39]. A highly statistically 
significant progression-free survival benefit is observed during rituximab maintenance. This 
advantage is not translated to a statistically significant overall survival benefit after first 
induction treatment in patients with follicular lymphoma. This may be because a longer follow-
up is required to demonstrate a statistically significant difference in survival of patients in first 
remission whose estimated survival is in the range of decades, as opposed to few years in 
patients in second or third remission [41]. 
However, most of these patients are not cured and experience relapse after a median of 
4 years [41]. Moreover, rituximab maintenance treatment was associated with a higher rate of 
grade 3 or 4 adverse events and with a higher rate of infections compared with the no 
maintenance [41].  
Rituximab tolerability and mechanisms of resistance 
Adverse events were reported in 84% of patients receiving rituximab, during therapy or 
within the first 30 days following treatment. The most common adverse effects were infusion-
related reactions and lymphopenia. Serious adverse effects included severe infusion related 
reactions, tumor lysis syndrome, mucocutaneous reactions, hypersensitivity reactions, cardiac 
arrhythmias, angina, and renal failure. One possible haematological adverse event is the 
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reduction in peripheral B lymphocyte counts, which can last for up to 6 months with a recovery 
period of 9 to 12 months [39]. 
Despite being the most successful anti-cancer mAb to date, the effectiveness of 
rituximab is ultimately limited due to the development of resistance with relapse of the 
disease. About 30% of patients with aggressive B-NHL develop primary resistance mechanisms, 
whereas a fraction of indolent B-NHL acquires rituximab resistance only after relapsing [19]. It is 
currently unclear, whether such secondary resistance to rituximab is based on similar 
mechanisms as primary unresponsiveness; however, it was demonstrated that rituximab 
resistance is mediated by both tumor and host factors. Lymphoma cells are able to increase the 
expression of complement regulatory proteins that impair CDC and ADCC, and to overexpress 
anti-apoptotic proteins or down regulate pro-apoptotic proteins [37]. The CD20 molecule itself 
can be involved in resistance to rituximab, by down-modulation, structural changes or loss of its 
expression. Reduction or loss of CD20 cell surface expression following rituximab treatment has 
been reported in some patients with B-CLL, and seems to depend on epigenetic mechanisms 
involving the CD20 promoter or CD20-regulating transcription factors [19].  The immune 
recognition of CD20-bound rituximab can also depend on the patients’ genetic background. 
Specific FcR or complement component polymorphisms correlate with reduced efficacy of 
rituximab-based immunotherapy. A well-defined example is the FcR polymorphism FcRIIIa-
V158F, which is associated with impaired ADCC in FL, even if it failed to predict the response to 
rituximab in CLL [19,37,42]. Host-related resistance may be mediated also by exhaustion of 
complement components or effector cells [37]. 
To overcome these limitations and the onset of rituximab resistance, many combination 
therapies have been proposed to modulate intracellular signal transduction, to inhibit 
proliferation, and to induce apoptosis. For example, combining rituximab with inhibitors of 
specific pathways involved in CD20 down-modulation, such as Temsirolimus, or with anti-
proliferative agents able to sensitize lymphoma cells to rituximab, like Bortezomib, or with 
immunostimulatory molecules, which can boost ADCC, as GM-CSF or IL-2 [19,37]. 
Disappointingly, response rates to these combination treatment were not significantly different 
from those obtained with rituximab alone [37].  
One of the main advantages of passive immunotherapy employing mAbs, is the relative 
independence by the patient’s immune system—which may be dysfunctional because of tumor 
burden or prior therapies—to initiate a response. However, as the targeted lymphoma cells 
mutate, down-regulate, or otherwise alter the targeted antigen, the main disadvantage is the 
development of resistance to therapy [5]. 
Cell-based therapy 
Besides mAb, as described above, the efficacy of cell-based therapies in B-NHL has been 
repeatedly proved by different clinical trials, testing allogeneic transplantation, donor-
lymphocyte infusion (DLI), and therapies using ex vivo expanded T and NK cells, such as 
lymphokine-activated killer cells, cytokine-induced killer cells, or CD3/CD28-expanded cells. The 
therapeutic index of such therapies might be improved by specifically targeting lymphoma 
antigens. Early attempts employed T cells with a natural T-cell receptor selected ex vivo to 
target EBV antigens expressed by distinct lymphoma histotypes [43]. However, a major 
limitation of adoptive T-cell transfer is the potential to select escape tumor variants, because 
these therapies are inherently restricted to a single or a few antigen targets. Still, T cells have 
several advantages as compared with mAbs, including their capacity to migrate to sites of 
lymphoma, to proliferate, and to take advantage of the lymphodepleting effects of standard 
cytotoxic therapies [5]. 
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Active immunotherapy for low-grade B-cell lymphomas 
In addition to the aforementioned therapeutic choices, many efforts have been done to 
develop non-toxic approaches as consolidation therapy for different types of B-NHL, after the 
induction of a first remission with traditional, mAb- or cell-therapy. Agents used for 
consolidation therapy should ideally have a different mechanism of action compared to 
induction therapy, because residual tumor cells can be resistant to these approaches. 
Moreover, they should be safe, improve the duration of remission, and they should not 
preclude the efficacy of future therapies [44]. In this context, an alternative approach is to 
vaccinate the patient with a pool of potential target antigens and to allow the immune system 
to select the most effective BCRs and T-cell receptors (TCRs) [5]. So, the immune system can 
select novel target overlooked by the guided process of passive immunotherapy and develop a 
polyclonal response directed against multiple epitopes, hence limiting tumor escape that gives 
rise to relapse [5,37]. On the other hand, the disadvantage of active immunotherapy is its 
reliance on the patient’s immune system, which may be dysfunctional after the former cycles of 
chemotherapy [37]. Therefore, the most suitable candidates for active immunotherapy 
approaches are patients affected by indolent FL in first remission. The indolent nature of FL 
allows the patients’ immune system to recover from the immunesuppression induced by 
previous therapies. In addition, FL is regarded as particularly immune responsive based on high 
response rates to mAb treatment, occasional responsiveness to interferon-α and IL-2, and 
correlation of survival time with gene expression profile of tumor infiltrating immune cells, and 
especially with the expression of genes encoding T-cell markers [37,45]. 
Active immunotherapy trials so far consist largely on vaccines that use the 
immunoglobulin Id as a tumor-specific antigen. A major obstacle in production of Id vaccines 
derives from their patient-specific nature that requires the generation of a custom-made 
product. However, Id may be actually used as either protein or DNA in therapeutic vaccines 
[37]. Id vaccination does not induce immunosuppression, through its mechanism of action it 
should bypass the development of resistance to rituximab, and does not interfere with possible 
future therapies. Thus, Id vaccines are ideal candidate as consolidation therapy, and may 
prolong remission duration without risks associated with currently available consolidation 
therapies [44]. Nevertheless, unlike passive immunotherapy, regulatory approval has not yet 
been granted to any regimen of active immunotherapy for lymphoma, despite evidence of 
biological and clinical efficacy as well as clinical benefit of Id vaccination in lymphoma patients 
[37]. Further studies and clinical trials are therefore required to consolidate the potentiality of 
this promising therapeutic approach, in particular as maintenance therapy. 
The idiotype as a target for tumor vaccination 
Idiotype features 
Unlike most other proteins, which, from an immunological standpoint, can function only 
as antigens, antibodies can function both as antigen-recognizing and -binding molecules and as 
antigens by virtue of several types of epitopes found on their heavy and light chains [46]. Each 
B lymphocyte expresses on its surface an immunoglobulin (Ig) molecule, capable of recognizing 
and binding to a unique epitope. This unique molecular structure is based on the variable 
regions of the heavy and light chains, and the hypervariable region of the antibody is called the 
Idiotype (Id) [15] (Figure 4). The Ig sequences differ in 3 short sections within the variable 
regions (V) of the heavy (H) and light (L) chains, called hypervariable regions or 
Complementarity-Determining Regions (CDRs). The assembly of the 3 VH-CDRs with the same 
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regions in the VL develops in a three-dimensional structure responsible for the antigen binding 
(the BCR). Antigen recognition depends specially by the CDR3 region, which is the closest to the 
C-terminal sequence and the most variable one. The extreme variability of the BCR structures 
allows the development of immune responses against a broad number of foreign antigens. 
Sequence variability arises from the differential usage of several genes, from the genetic 
recombination, and from the somatic hypermutation. The Ig chains are defined by 3 distinct 
gene loci, which respectively encode for the light chain κ, the light chain λ, and the heavy 
chains. The rearrangement, which concerns in particular genes encoding for the variable 
regions, entails random nucleotide insertions or deletions in the junction points among the V, 
D, and J segments, and thus results in genes with different sequence and length. Accordingly, 1 
x 10
8
 to 1 x 10
12
 possible recombinations may potentially encode different BCR structures.  
 
Figure 4. Immunoglobulin structure and idiotype features
3
. 
Since B-cell lymphomas are clonal in nature, arising from a single B-cell, the Ig 
rearrangement is preserved by the neoplastic clone, and the consequent Id results differently 
expressed from the Id of their non-malignant counterparts. Therefore, the Id is regarded as a 
tumor-specific antigen that can be targeted by immunotherapy [37], provided that the tumor 
cells express it on their cell membrane either intact as it is in its regular function as B-cell 
receptor and/or in the form of idiotopes associated with the HLA molecules for epitope 
presentation [46]. Idiotopes are hence defined as a peculiar variety of antigenic determinants 
or epitopes exclusively found on the immunoglobulin's heavy and light chain variable regions. 
The variable region of the tumor immunoglobulin is different from patient to patient, 
thus the Id is considered patient-specific and is not a universal tumor antigen. Therefore, the 
use of idiotype as a therapeutic lymphoma vaccine would require the generation of a custom-
made product for each patient [6]. 
 
                                                     
3
 http://www.inflammation.dk/iir/05ig/_igx.htm 
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Successes and failures of current idiotypic vaccination for B-cell Non-Hodgkin Lymphomas 
Compared to the passive anti-Id mAb therapy, abandoned relatively soon due to the 
onset of Id variants not targetable by the Id-specific Ab, anti-Id vaccination is able to induce a 
more complete immune activation generating a polyclonal Id-specific humoral and cellular 
immune response. Since the contribution of both humoral and cellular immunity to reach a 
survival benefit is still under investigation, it should be highly desirable to elicit both of them 
[46]. Furthermore, to enhance the immunogenicity of the native Id, based on preclinical and 
early clinical studies, the Id protein has been coupled to the powerful immunogenic keyhole 
limpet hemocyanin (KLH) with the addition of granulocyte–macrophage colony-stimulating 
factor (GM-CSF), which facilitates the induction of tumor-specific CD8
+
 T-cells [37]. Id-KLH 
coupled formulation is usually administrated subcutaneously on day 1 of the therapeutic 
schedule together with a dose of GM-CSF, which is subsequently delivered over the following 3 
days. GM-CSF dose and vaccination plan may vary from trial to trial [46]. The antigen is uptaken 
in the skin by APCs, thus inducing their activation and migration to lymph nodes, where T cell 
priming takes place. 
Two phase I/II clinical trials performed with this vaccine formulation in FL patients in 
first chemotherapy-induced complete remission, showed the generation of an Id-specific 
immune response, the clearance of residual tumor cells detected by PCR, and an enhancement 
of progression-free survival [47,48] (Figure 5). In a phase II study performed in a second 
chemotherapy-induced complete response, the Id-KLH plus GM-CSF formulation induced a 
specific immune response in the majority of patients (80%) with FL, and a highly significant 
increase in disease-free survival [49]. Moreover, in a phase II trial in patients with measurable 
disease, Id-vaccination alone was able to induce tumor regression and durable clinical response 
[50] (Figure 5). 
 
Figure 5. Summary of immunological and clinical outcomes in Id vaccine trials in B-cell NHL [6].  
Id proteins were generated through hybridoma techniques as in the Bendandi et al [47] 
clinical trial, or by recombinant production, through PCR amplification of the tumor-specific 
variable region Ig sequences and cloning into expression vectors carrying the desired isotype 
backbone [48]. The MyVax® phase I/II clinical trial sponsored by the Genitope Corporation 
(Fremont, CA) demonstrated that the recombinant Id was well-tolerated, and that 
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immunogenicity was comparable to that of hybridoma-derived Id. Moreover, induced serum 
anti-Id antibodies recognized native tumor Id structure as well as recombinant Id, and could 
specifically bind to patient's tumor cells [48]. This technology has the advantage of a reduced 
time to obtain the Id-formulation, and it does not need a surgical biopsy, as adequate tumor 
cells can be obtained by core needle biopsy, bone marrow aspiration or sampling of involved 
peripheral blood. The phase III clinical trial employing this vaccine formulation corroborated the 
capability of this technique to obtain Id protein in more than 99% of cases in which tumor cells 
express surface Ig [48]. 
Nevertheless, this double-blind, randomized phase III study, as well as the clinical trial 
sponsored by Favrille Inc, found no statistically significant differences in PFS between the Id–
KLH plus GM-CSF vaccine and a control vaccine containing KLH plus GM-CSF, although the 
vaccine was generally safe [51]
4
. An interesting correlation between clinical and immune 
response was highlighted in the Genitope study, showing an increased progression-free survival 
in patients developing an anti-Id immune response, compared to patients who did not mounted 
such a response (40 versus 16 months). This observation suggests that there can be a group of 
patients, who may benefit from the Id vaccination [37]. In addition to these clinical trials, 
another phase III study was performed by NCI/Biovest International, and demonstrated an 
improved disease free survival (p=0.045) in Id-vaccinated patients if compared to the control 
arm [14] (Figure 6). This trial was criticized because it did not reach the sample size and the 
statistical power (p<0.01) originally planned [37,46]. 
 
Figure 6. Phase III idiotype vaccine clinical trials. A. Scheme summarizing similarities and differences between the 
three trials [6]. NCI – National Cancer Institute; q 3w – every 3 weeks; FNA – fine needle aspiration; PD – 
progressive disease; DFS – disease-free survival; PFS – progression-free survival; TTP – time to progression. B. Time 
to progression of intent-to-treat population in Favrille study [51]. C. Disease-free survival for randomly assigned 
patients who received at least one dose of Id vaccine (n=76) or control (n=41) in the NCI/Biovest study [14]. 
                                                     
4
 Levy,R., Robertson, M.J., Ganjoo,K., Leonard,J., Vose,J., andDenney,D.(2008). Results of a phase 3 trial 
evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) 
with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-
Hodgkin’s lymphoma.  American Association for Cancer Research Meeting Abstract, San Diego, LB-204. 
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There are several factors, which differentiated the 3 studies and can be responsible for 
the different clinical outcome observed. First patients’ eligibility criteria: in Biovest study only 
patients in complete remission were recruited, conversely Genitope and Favrille also included 
patients who achieved only partial response or even stable disease after chemotherapy [3]. The 
persistence of significant numbers of malignant cells may make the immune environment 
unfavorable for the development of an adequate immune response to the vaccine [15]. In 
addition, the pre-vaccine therapy was different in the 3 trials, with the Favrille trial being the 
only one employing rituximab instead of chemotherapy as debulking agent [51]. Moreover, 
while Genitope and Favrille trials used recombinant Id and exclusively with the IgG isotype, 
Biovest vaccination was performed with hybridoma products, which could express either IgG or 
IgM isotypes [37]. Interestingly, the latter trial revealed that vaccination with IgM-Id but not 
with IgG-Id significantly prolonged disease free survival compared with isotype-matched 
controls, suggesting that the isotype of the constant region may influence the immunogenicity 
of variable region epitopes [14]. Preclinical studies investigated and beard this hypothesis 
showing that Ids switching to IgG became tolerogenic, whereas Ids of their IgM progenitors 
were highly immunogenic [52,53]. These findings suggest that the determination of the Id 
isotype may facilitate early identification of patients who are more likely to benefit from a 
vaccine approach [15], and that the Id produced by hybridoma technique may resemble more 
closely the native Ig on the tumor cell surface, compared with the recombinant DNA–derived Id 
proteins [14,44]. 
Notwithstanding, some observations have to be done about the real failure of Id 
vaccination. The lack of a statistical significance in progression-free survival between patients 
receiving vaccination and those receiving the control may be due to factors other than 
vaccination efficacy [46]. Thus, consideration should be given not only to the clinical benefit, 
which is the capacity to influence disease endpoints, but also to biological and clinical efficacy, 
which indicate respectively the vaccine capacity to elicit an immune response and to induce in 
vivo anti-tumor effects [46]. Moreover, considering that the current standard of care for FL 
includes the use of rituximab, a careful investigation should be done on the effects of B-cell 
depletion on vaccination T-cell priming [37]. Indeed, while some mouse models suggest that B-
cells inhibit the induction of T-cell dependent immunity, skewing the T-helper response 
towards a T helper 2 profile, others prompt that B lymphocytes are necessary for T-cell priming 
[6]. 
Increasing antigen immunogenicity, delivery and presentation are other major issues of 
Id-vaccination. The co-administration of the Id-vaccines with immunostimulatory adjuvants as 
CpG may enhance the immunogenicity, activating antigen presenting cells, B cells, and NK cells 
by engaging TLR9 [37]. These reagents were employed also in a recent phase I study of in situ 
vaccination, which consists of low-dose irradiation to a single lymphoma site, followed by 
intratumoral injection of CpG at the same site. The first results were encouraging and showed 
that the in situ vaccination was able to induce tumor-reactive CD8
+
 T cells [54]. In addition, 
incorporation of Id into cytokine-carrying liposomes has been proposed as a tool to enhance Id 
delivery [37]. Dendritic cells (DCs) loaded in vitro with antigen are also attractive vehicles for 
therapeutic cancer vaccines [37]. In this respect, Di Nicola et al., in a pilot study recruiting 18 
patients with measurable indolent NHL who had relapsed after at least one chemoradiotherapy 
regimen, used unfractionated whole tumor cell preparations as the source of antigens. DCs 
were loaded with heat-shocked apoptotic and necrotic tumor cells. The vaccination was well 
tolerated without autoimmune reactions, achieved significant objective clinical responses, with 
enhanced antitumor activity in 6 patients (3 objective radiographic complete responses and 3 
partial responses), and was associated with significant immune modulation [55]. The authors 
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selected the whole tumor as a source of antigen with the intent to promote activation of 
immune responses not only to tumor-specific Ig heavy chain-encoded epitopes, but also to the 
wide array of recently identified shared lymphoma-associated antigens recognized by T cells in 
NHL patients [55]. On these grounds, the identification of universally expressed lymphoma-
specific antigens will be useful in the future to develop vaccine formulations that can be used in 
all lymphoma patients, being therefore easier and less costly to produce [6]. 
Idiotype characterization of different lymphoproliferations 
Recent evidence suggests that the limitations due to the individualized production of Id-
vaccines may be overcome. In fact, distinct set of stereotyped Ig have been identified in several 
subsets of B-NHL, suggesting that a much higher frequency of Id sharing exists among patients 
than appreciated previously [56]. In this context, sequencing of the immunoglobulin variable 
regions genes in 21 HCV-associated NHLs revealed a highly restricted use of gene segments, 
with all variable regions of the VH chain using exclusively the VH1, VH3 and VH4 family and the 
majority of VK chains expressing the kv325 (VK3-20) and the kv328 (VK3-15) genes [57]. The 
same VH family members were observed in 13 patients affected by Sjögren’s Syndrome cell 
lymphoproliferative disorders, which also preferentially expressed a VK3 family gene [58].  
A biased usage of particular VH segments has been reported also in MALT lymphomas. 
Gastric MALT inflammation-dependent tumors frequently used VH3-23 and VH3-30 fragments, 
which have been closely associated also with autoimmune diseases. Indeed, they have been 
frequently used in thymic MALT lymphoma, a tumor closely associated with autoimmune 
disease [59]; while salivary MALT lymphomas B-cells mainly express VH1-69 [60].  
Some papers revealed also the shared use of a specific Ig rearrangement in different 
lymphoma histotypes, as for example the expression of VH4-34 frequently found in diffuse 
large-cell lymphoma, primary central nervous system lymphoma, B-chronic lymphocytic 
leukemia (CLL), and autoimmune disorders, and expressed in about 5% of healthy adult B 
lymphocytes [61]. 
In CLL, the mutational status of the immunoglobulin genes expressed in tumor B-cells 
can be used to segregate patients into 2 subsets that have significantly different rates of 
disease progression: the unmutated VH genes are associated with a greater tendency for 
disease progression and shorter survival than the mutated ones. Within the unmutated group 
several studies revealed that the Ig repertoire shows a reduce variability compared with that of 
adult blood B cells, with a frequent use of VH1-69, VH3-07, VH3-21, and VH4-34, and a skewed 
D3-3 and J6 gene usage with restricted reading frames (RFs) in particularly linked to the VH1-69 
expression [30,31]. Some of these IGHV genes have also been implicated with prognosis: the 
VH1-69 was associated with a poor prognosis, VH3-48 and VH3-53 were predominantly found in 
female patients without adverse prognostic cytogenetics, and VH3-72 was associated with 
highly stable disease [62]. 
Some recent papers aimed to assign the stereotyped BCRs observed in CLL patients to 
defined clusters identified by shared HCDR3 motifs. These analysis, carried out on very broad 
cohorts of patients, revealed an over-representation of certain IGHV genes among clustered 
cases, especially VH3-21 and VH1-69, and an under-presentation of others, as for example VH3-7, 
VH3-23, VH3-30 [27-29]. Interestingly, Darzentas et al. observed that just six IGHV genes (VH1-
69, VH1-3, VH1-2, VH3-21, VH4-34 and VH4-39) accounted for almost 80% of cases belonging to 
high-level clusters with stereotyped BCR structures [29]. 
The restricted use of specific gene segments in many different lymphomas is unlikely to 
occur by chance only, thus leading to the speculation of a possible antigen component involved 
in the neoplastic transformation of CLL and other B-NHLs [30,57]. Moreover, the limited 
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repertoire of the Ig expressed by different B-NHLs could be potentially exploited for the 
development of tailored treatment strategies applicable to each major stereotyped subset 
[27,31]. 
Thus, the identification of T-cell epitopes shared by multiple patients, may overcome 
one of the major limitations of current Id-vaccination, which is the requirement of 
individualized manufacturing [63]. In 2000, Trojan et al. described the generation of autologous 
T cells specific for framework-derived peptides from patients with CLL [64]. This observation 
may indicate that there is neither a defect in the T-cell repertoire against such self peptides, nor 
T-cell tolerance, or simply that ex vivo presentation of such peptides in the context of 
professional antigen-presenting cells might have been capable of overcoming any in vivo 
tolerance [64]. In this field, other 2 more recent papers demonstrated the induction of epitope-
specific T cells stimulating healthy donors PBMCs with Ig-derived peptides shared by different 
families of both heavy [65] and light immunoglobulin chains [63]. The immunogenic epitopes 
were selected for their shared expression in several lymphoma patients-derived sequences, and 
were localized in both the complementarity determining regions and the framework regions 
[63,65]. This strategy may be useful to selectively expand Id-specific T cells ex vivo in order to 
generate "educated" DLI [63], or even better to develop a shared vaccine [27]. However, for the 
latter hypothesis, it will be important to determine whether Ig light chain–specific cytotoxic T 
lymphocytes (CTLs) preexist in the blood of patients with B-cell tumors and whether such 
precursors can be expanded by vaccination or adoptive transfer [63]. 
IGHV1-69 as a promising candidate for a shared immunotherapy 
The identification of a common antigen expressed on B-cell malignancies, and 
preferentially not present on normal B cells, could offer a potential for the development of an 
off-the-shelf vaccine for lymphoma, which avoid the expensive, laborious and time-consuming 
production of patient-specific therapies [66]. To prevent the induction of autoimmunity, tumor-
associated antigens should be uniquely expressed or overexpressed in lymphoma cells 
compared with normal B-cells [63].  
In this respect, a recent paper from Weng et al., selected the T-cell leukemia/lymphoma 
1 (TCL1) oncoprotein as an aberrantly expressed antigen in many B-cell malignancies, including 
FL, CLL, MCL, DLBCL, and SMZL, and identified TCL171-78 as the minimal epitope that binds to 
HLA-A*0201. They were able to generate peptide-specific CTLs lines from HLA-A*0201 healthy 
donors and patients, and these CTLs can efficiently kill lymphoma cell lines and primary human 
lymphoma cells [63]. These results suggested that TCL1 protein is naturally processed and 
presented on the surface of primary lymphoma cells for recognition by CTLs in an HLA-
restricted manner. Moreover, since recognition by antigen-specific CTLs needs only few MHC-
peptide complexes on the cell surface, also low-expressing lymphoma cells can be specifically 
killed. Furthermore, lysis of TCL1-expressing tumor cells by TCL1-specific CTL may potentially 
induce epitope spreading and broaden the immune response against tumor cells with or 
without TCL1 expression [67]. 
These data pave the way to identify and characterize shared antigens among B-cell 
lymphomas in a broader MHC background, in order to develop a vaccine therapy for wide 
lymphoma patients’ subsets. 
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Lessons from IGKV3-20 
In this respect, we recently characterized the immunogenic properties of IGKV3-20 and 
IGKV3-15 proteins [56], highly expressed, as mentioned above, in HCV-associated lymphomas 
autoimmunity-associated lymphoproliferations, DLBCL, MZL, FL, and CLL (Figure 7) [30,58,68-
73]. We found IGKV3-20 and IGKV3-15-specific T-cell and humoral responses in NHL patients, 
and proved that these 2 proteins are immunogenic ex vivo. The 2 targets were able to elicit 
specific CTLs that cross-react against related IGVK proteins expressed by different lymphomas. 
These results suggest that the interpatient variation in the IGKV3-20 or IGKV3-15 amino acid 
sequence does not constitute a major limitation in inducing cross-reactive responses. Actually, 
CTLs induced with a "prototypic" IGKV3-20 protein were able to specifically kill autologous 
targets loaded with idiotypic VK proteins of the same subfamily derived from unrelated NHL. 
Moreover, when generated from the PBMCs of HLA-A*0201 donors, IGKV3-20-stimulated-CTLs 
specifically recognized also 2 different lymphoma cell lines respectively expressing IGKV3-20 
and IGK3-15 in a HLA-A*0201 restricted manner (Figure 7). These findings demonstrate that the 
2 proteins are naturally processed in lymphoid cells and confirm the ability to induce cross-
reactive responses against proteins characterized by a sequence homology of >80%, as IGKV3-
20 and IGKV3-15. In addition, the identification of MHC-class I restricted epitopes within IGKV3-
20 protein and the generation of epitope-specific CTLs able to recognize also similar and variant 
epitope in IGKV3-15, demonstrated that IGKV3-20 protein carries natural heteroclytic versions 
of several CTL epitopes in the IGK proteins broadly expressed among lymphoid malignancies. 
Finally, through the immunization of mice with KLH-conjugated IGKV3-20, we demonstrated 
also the in vivo induction of humoral and T-cell responses against IGKV3-20, as well as the 
cross-reactivity of IGKV3-20 CTL responses [56]. These results may also rule out the lack of 
specificity against these Id proteins in the TCR repertoire due to central tolerance, and/or the 
occurrence of peripheral tolerance [56]. 
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Figure 7. Characterization of IGKV3-15 and IGKV3-20 expression and immunogenicity features. A. Summary table 
of IGKV3-15, IGKV3-20, and in general IGKV3 proteins expression among B-cell lymphoproliferations. B. Results of 
cytotoxic assays performed with IGKV3-20-induced CTLs. DG75 (IGKV3-20
+
) and SH9 (IGKV3-15
+
) cells were 
efficiently killed in a HLA-A*0201–restricted manner (cr11.351 mAb) by IGKV3-20–specific CTLs obtained from 
donors single-matched for HLA-A*0201 with target cells. Effector:Target ratio - 20:1. IGKV3

 LCLs and BARF1 p29 
pulsed LCL were used as negative controls (P < 0.02, Student t test) [56]. 
Previous papers supported the IGKV3-20 eligibility as a promising target for a shared 
immunotherapy to B-NHL. In particular, a multiparametric investigation of markers of immune 
response induced in human monocyte-derived dendritic cells, demonstrated an immune 
activation and responsiveness after IGKV3-20 stimulation, with a prevalence of Th2-cytokines 
production. Moreover, HCV-seropositivity did not impair the immune activation induced by 
IGKV3-20, thus confirming the potential utility of this protein also in HCV-associated 
lymphomas [74]. Such results have a prospective application in the development of idiotype 
based on the IGKV3-20 protein, suggesting that a specific Th1-driving adjuvant formulation 
should be adopted to elicit therapeutically relevant immune responses [75]. 
In addition, a method to optimize Id vaccines was developed expressing IGKV3-20 in 
mature DC with the use of recombinant lentivirus. The protein was fused to the Gly-Ala repeat 
domain of the Epstein-Barr virus nuclear antigen (EBNA) 1, which act as a portable inhibitor of 
proteasomal degradation, in order to improve antigen stability. The manipulation of the 
antigen processing machinery allowed reshaping the Id-specific immune response. Indeed, this 
strategy induced effective responses to subdominant epitopes that could bypass the tolerance 
to self antigens expressed in malignant cells [76]. 
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Shared IGHV1-69 expression among different lymphoproliferative diseases 
On the bases of the previous considerations, other Id proteins, expressed by different B-
NHLs, could be investigated as targets of a shared immunotherapy. Among the various 
stereotyped immunoglobulins found in B-NHL, IGHV1-69 could constitute a good candidate for 
the development of a therapeutic vaccination because of its wide expression, identified also in 
pre-malignant lymphoproliferations (Figure 8). Indeed, in type II mixed cryoglobulinemia (MC), 
HCV-infection drives a non-malignant expansion of monoclonal B-cells, which produce a 
polyreactive natural antibody of the IgM class commonly encoded by the VH1-69 variable gene 
[77]. This VH gene, together with the VLkv325, was found highly overrepresented also in HCV-
associated immunocytoma, suggesting that HCV-associated immunocytoma most likely 
represents the malignant counterpart of type II MC [71].  
Moreover, sequencing of the clonal VH genes found in lymphoepithelial (myoepithelial) 
sialadenitis, a reactive infiltrate that frequently characterizes Sjögren’s syndrome, revealed the 
use of VH1-69 gene in 61% of cases [60]. Also in this case, this non-malignant clonal B-cell 
expansion can evolve to salivary gland MALT lymphomas, which in turn express the IGHV1-69 
protein on lymphoma B-cells [60]. 
Furthermore, the VH1-69 gene is preferentially used also in nodal-marginal zone B-cell 
lymphoma, indicating a highly biased and non-random use of the VH segments in this subtype of 
tumors [61]. Sequence analysis of the rearranged VH segments in these tumors revealed a 
substantial deviation from the germline VH1-69 sequence with a degree of mutations very 
similar among the different cases of lymphoma [61].  
The VH1-69 immunoglobulin segment is expressed in the restricted repertoire of fetal 
liver B lymphocytes [78,79], and a productive VH1-69 is present in about 1.6% of normal B 
lymphocytes in adults [80]. However, the expression of this gene results much more prevalent 
in lymphoma B-cells, and in particular it characterizes 13% of all CLL and 25% to 30% of un-
mutated CLL [31,81]. Again the sequence analysis performed in a large cohort of CLL patients 
revealed that VH1-69 sequence in normal B cells did not reflect the corresponding sequence in 
CLL [81]. 
 
 
 
INTRODUCTION______________________________________________________________ 
 26 
 
Figure 8. IGHV1-69 documented expression in different B-cell lymphoproliferations. 1. Flow cytometric analysis of 
B cells expressing the G6 (IGHV1-69) Idiotype in HCV
+
 type-II cryoglobulinemia (cryo-II). A. Healthy subject. B. Cryo-
II patient with mild blood invasion by G6
+
 cells. C. Cryo-II patient with more pronounced blood invasion by G6
+
 
cells. Extracted and modified from [77]. 2. Distribution of VH genes in HCV-associated immunocytomas. 51p1 gene 
encodes for IGHV1-69 protein. Extracted and modified from [71].  3. VH, D, and JH usage and HCV infection in 
Nodal Marginal Zone B-Cell Lymphoma. Extracted and modified from [61]. 4. Usage of immunoglobulin heavy-
chain variable (IGHV) subgroups and IGHV genes and chance to belong to clusters of homologous heavy chain 
complementarity determining region-3 (HCDR3) in Chronic Lymphocytic Leukaemia. Expression of the ten most 
frequently used IGHV genes. For each IGHV gene, histograms reported the total number of IG rearrangements 
(closed histograms), the total number of IG rearrangements not included in clusters of homologous HCDR3 (open 
histograms) and the total number of IG rearrangements included in clusters of homologous HCDR3 (dotted 
histograms). Extracted and modified from [28]. 5. Deduced amino acid sequences of the consensus lymphoma VH 
gene segments in salivary gland MALT lymphomas. The sequences are compared to the amino acid sequences of 
the germline VH gene segments showing the greatest homology where identity is indicated by a dot. The positions 
of mutations in the nucleotide sequences that would not result in a change in amino acid sequence are indicated 
by small case letters. Extracted and modified from [60]. 
Could the shared expression of IGHV1-69 imply a chronic antigenic stimulation? 
The frequent occurrence of stereotyped receptors in different lymphoma patients raises 
the question on the nature of the molecules they can effectively recognize. In this regard, the 
almost identical CDR3 sequence of the IGHV1-69 protein expressed in HCV chronic infection 
suggests that a same or similar HCV antigen epitope may be responsible for the B-cell selection 
by a direct antigenic stimulation [61]. This hypothesis is also sustained by the observation that 
hybridomas derived from the peripheral B cells of HCV-infected patients and selected by 
reactivity with the viral E2 glycoprotein, used highly restricted VH genes, with a prevalence of 
VH1-69 [69]. Taken together, these studies strongly support the concept that the growth and 
survival of monoclonal B cells in HCV-associated lymphoproliferative disorders depend strictly 
on the continued stimulation by HCV [77]. 
The frequent usage of the VH1-69 gene in autoimmunity-associated 
lymphoproliferations suggests a similar chronic stimulation due to auto-antigens, as for 
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example the rheumatoid factor in salivary gland MALT lymphomas. Indeed, the expression of 
IGHV1-69 is frequently observed in antibodies with rheumatoid activity in patients with salivary 
gland lymphomas and/or Sjögren’s syndrome [60]. Conversely, gastric MALT lymphomas do not 
usually express IGHV1-69, thus suggesting that pathogenesis of MALT lymphomas may have 
features that are specific for certain sites or locations [60]. 
A mechanism involving autoreactive antibodies, or bacterial antigens, or antigenic 
epitopes present on viable and apoptotic T cells, was proposed also in the pathogenesis of CLL 
[62]. Even if the trigger of this disease is still not known, the stereotyped immunoglobulin 
repertoire in CLL suggests that its development and evolution is not a stochastic event, but may 
be favoured by an antigen that drives the cell of origin for at least some subsets of CLL [29]. 
Several IGHV1-69 expressing IgM obtained from CLL cases showed reactivity against apoptotic 
cells, while others recognized polysaccharide derived from Streptococcus pneumoniae [81]. 
Moreover, a typical characteristic of CLL is the presence of a sizeable amount of normal 
activated CD3
+
CD4
+
CD40L
+
 T cells, which themselves are a sign of chronic inflammation [82]. In 
addition, CLL cells have the phenotypic profile of B cells activated by antigen interaction and 
display a gene expression profile that also recalls that of antigen-experienced B lymphocytes 
[82]. In particular, B-CLL-derived mAbs characterized by the un-mutated rearrangements 
involving IGHV1-69 were shown to selectively bind a molecule of 250 kDa, identified as non-
muscle myosin heavy chain IIA, a major molecular motor of normal cells [83]. It is interesting to 
note that this molecule transmigrates to the cell surface of cells undergoing programmed cell 
death, thus sustaining the hypothesis of an autoreactivity against apoptotic cells [82]. 
Interestingly, autoantibodies against non-muscle myosin have been reported to occur also in 
the setting of HCV infection [84]. 
The use of IGHV1-69 was recently documented in recombinant antibodies against 
different viruses as HIV, SARS and influenza [85-88]. In this context, a recent paper describes 
the ability of CLL recombinant antibodies encoded by IGHV1-69 to react with pUL32, a 
phosphoprotein of cytomegalovirus (CMV). CMV has been linked to CLL by several lines of 
evidence: rates of CMV seroprevalence, frequency, and magnitude of CMV reactivation, and 
risk for CLL increase in parallel with increasing age [89]. In addition, an expansion of 
perforin
+
CD4
+
 T cells was observed in the peripheral blood of CLL patients, and it was strongly 
associated with CMV seropositivity [90]. These perforin
+
CD4
+ 
T population was enriched for 
MHC class II-restricted, CMV-specific cells, indicating a direct role for CMV in promoting their 
expansion, and characterized by a IL4
+
 and IL10
+
 phenotype, thus driving a Th2 response. 
Hence, it is possible that anti-CMV CD4
+
 T cells could support further B-CLL expansion [90]. 
Finally, a more pronounced expansion of CMV-specific CD8
+
 T cells was observed in CLL patients 
than in age-matched healthy adults, suggesting that an antigenic determinant of CMV could be 
involved as a specific antigen or superantigen in BCR-mediated stimulation of CLL cells [89]. It is 
interesting to observe that the IGHV1-69 expressed on the majority of normal B-cells are 
distinct from those expressed on leukemic cells, and that there is only a little subset of healthy 
B-cells expressing 51p1-encoded IGHV similar to those found in CLL. This suggests that, 
conceivably, a subset of such normal B cells may be selected to undergo transformation by 
virtue of their expression of surface Ig with some distinctive binding activity to specific antigens, 
as for example the pUL32 of CMV [89]. 
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Immune monitoring for cancer immunotherapy 
One of the main challenges of tumor vaccination is the identification of suitable 
biomarkers of response to the therapy, which could have a reliable correlation with a 
meaningful clinical endpoint. In this respect, the measurement of T-cell mediated immune 
responses has been widely investigated in order to validate shared protocols for the immune 
monitoring during cancer immunotherapy [91,92]. 
The most common biomarker used in cancer vaccine protocols has been the immune 
response of patients to TAA pre- and post-vaccination. Some trials have analysed also the 
antibody response to TAA, or variations in the percentage of Treg, myeloid derived suppressor 
cells, NK and DCs, often evaluating the ratio of effector to regulatory cells. In addition, many 
studies have used analysis of multiple serum cytokines and chemokines [3,93-98]. 
The study from Di Nicola et al., for example, documented significant changes in Treg, NK 
and anti-tumor T-cell frequencies, and humoral responses in responding patients compared 
with non-responding ones. These observations indicate that the clinical responses observed 
after tumor-loaded DC-based vaccination may be the result of an active modulatory effect on 
different components of the immune system [55]. Moreover, the responding patients carrying 
the HLA-A*0201 allele showed after vaccination an increase of IFN-γ and IL-4 releasing 
lymphocytes against peptides derived from the tumor specific IgH sequence. Notably, these 
responses were found up to 17 months after vaccination, suggesting a long lasting effect, if 
compared to other Id-vaccinations [55]. 
In this context, Id-specific T-cell lines were successfully generated from post-vaccine 
PBMCs of FL patients who had been actively immunized with the unique Id protein expressed 
by their tumors, which induced CD4
+
 and CD8
+
 T cell responses and molecular remissions [99]. 
The identification of such immunodominant epitopes in each Id protein may serve to validate 
suitable candidates for the development of reagents for immune monitoring in vaccinated 
patients. 
Many assays has been developed and improved in the last decades to perform immune 
monitoring. The multiparameter approaches used to characterized TAA-responses in vaccinated 
patients mainly comprise enzyme-linked immunosorbent spot (ELISPOT) to quantify the release 
of relevant cytokines (IFN-γ, IL2, IL-4 and IL-5) by TAA-stimulated T cells, flow cytometry 
identification of TAA-specific T cells through peptide-multimer complexes able to bind to the 
TCR on T cell surface, and intracellular staining to determine the production of multiple 
cytokines after in vitro stimulation of T lymphocytes with TAA. The latter two techniques can be 
combined in order to obtain a more complete profile of TAA-specific immune responses [100]. 
The enumeration of anti-tumor T cells through fluorochrome labeled multimers 
conjugate of MHC molecules with a tumor antigen peptide has the main advantage to detect 
rare T cell populations, due to the high sensitivity of these reagents [101-104]. Drawbacks are 
mainly linked to the necessity to know exactly which peptide to use and which HLA background 
characterized each patient [5]. The lack of information about the functional state of T cells 
identified with this technique could instead be bypassed by the combination of tetramer 
staining with surface markers of T cell memory status or activation [105-108], or with the 
measurement of T cell proliferation in response to antigen re-exposure in vitro [5]. 
In addition, combined with this approach, intracellular staining can simultaneously 
assess cell subtype and cytokine production and allow measurement of multiple cytokines 
within a single cell [5,109,110]. New evidence suggest that the quality of T cell responses, and 
especially the presence of multifunctional T cells, correlates with the disease outcome to 
various infections and with the induction of an effective anti-viral immune response after 
vaccination [111]. Accordingly, the incorporation of such T-cell assays in the design of future Id 
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vaccines could increase the sensitivity to identify relevant immunologic correlates of tumor 
regression or/and improved survival [48]. 
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AIM OF THE STUDY 
Idiotypic vaccinations were considered a promising therapeutic approach for the 
consolidation of compete remission in B-NHL patients after standard treatments and 
monoclonal antibodies. However, recent evidence coming from phase III clinical trials revealed 
the inability of 2 out of 3 studies to reach a significant increase in PFS, thus reducing confidence 
and trust placed in this kind of treatment. In our opinion, a better design and definition of the 
vaccine target and the clinical endpoints may increase the potentiality of Id vaccination, which 
can be regarded as an integrative adjuvant approach during the maintenance therapy for NHL 
patients in first remission. 
To this end, the identification of a common Id, shared by different B-cell 
lymphomas/leukemias, may overcome the patient-specificity of current Id vaccination and 
facilitate the identification of eligibility and responsiveness markers. We therefore identified 
IGHV1-69 as a promising candidate for the development of a shared immunotherapy for B-cell 
lymphoproliferations, due to the common expression of this protein in HCV-associated NHLs, 
autoimmunity-related lymphomas, and CLL [28,61,71,81]. Moreover, the presence of this Ig 
rearrangement in pre-malignant lymphoproliferations, as for example in type II mixed 
cryoglobulinemia, suggests a potential application of this protein also for preventative purposes 
[58,60,77]. 
On these grounds, the aim of this study was to characterize the ex vivo immunogenicity 
of IGHV1-69, and to select the most immunogenic epitopes in order to develop antigen-specific 
reagents for the identification of eligible patients and for the immune-monitoring of anti-tumor 
responses. In particular, we investigated the ability of this protein to induce epitope-specific T-
cell responses in lymphoma patients, and its efficiency in boosting these epitope-specific T-cells 
in vitro. Finally, we also evaluated if CTLs induced with epitopes derived from a selected IGHV1-
69 sequence, are able to cross-react against a cell line expressing a variant IGHV1-69 sequence. 
Such evidence could provide a strong premise for the development of recombinant Id vaccines, 
potentially able to elicit tumor-specific immune responses in a quite broad number of patients, 
affected by lymphoproliferative disorders expressing molecularly related Id. 
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MATERIALS AND METHODS 
Patients and Healthy Donors 
Peripheral blood samples from 23 patients with an IGHV1-69
+
 B-cell lymphoproliferation 
were collected for this study. Six samples were kindly provided by Prof. Salvatore De Vita and 
Dr. Martina Fabris (Clinic of Rheumatology, DSMB, University of Udine, Italy), 10 by Dr. Valter 
Gattei (Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, 
I.R.C.C.S., Aviano, PN, Italy), 6 by Dr. Massimo Di Nicola (“C. Gandini” Medical Oncology, Bone 
Marrow Transplantation Unit; Fondazione I.R.C.C.S., Istituto Nazionale per lo Studio e la Cura 
dei Tumori, National Cancer Institute, Milan, Italy), and 1 was collected at the Centro di 
Riferimento Oncologico, National Cancer Institute (I.R.C.C.S., Aviano, PN, Italy). IGHV1-69 
expression was determined by sequencing of IGHV amplicons derived from either reverse-
transcribed total RNA or genomic DNA [28,61]. Buffy coats from 51 healthy donors were also 
collected and included in this study.  
Peripheral blood mononuclear cells (PBMCs) were freshly isolated from heparinised 
blood of patients or from buffy coats of healthy donors by Ficoll-Hypaque gradient 
(Lymphoprep, Fresenius Kabi Norge Halden, Norway) using standard procedures, and viably 
frozen in fetal bovine serum (Gibco, Grand Island, NY) with 10% Dimethyl sulfoxide (DMSO), at -
180°C until use. 
Patient’s and healthy donor’s HLA-class I genotyping was performed by PCR sequencing 
based typing with primers specific for both locus A and B [112]. 
Cell lines and culture conditions 
The following human cell lines were used in this study: the transporter associated with 
antigen-processing-deficient T2 cells transfected with the HLA-A*0201 gene (T2-A2); the 
lymphoid C1R cell line, characterized by a low expression of its endogenous HLA class I antigens 
and transfected to express the HLA-A*0301 allele (C1R-A3; kindly provided by Prof Andrea 
Anichini, Department of Experimental Oncology, IRCCS Foundation, National Institute of 
Tumors, Milan, Italy); the lymphoblastoid cell line (LCL) PG B.95.8 (HLA-A*02; -A*03; -B*35; -
B*39) derived from the immortalization of peripheral B cells of a CLL patient through the 
standard EBV isolate B.95.8 (kindly provided by Dr. Javier Avila-Carino, Karolinska Institutet, 
Stockholm); the MHC-negative erythroleukemia K562 cell line; EBV-transformed LCLs generated 
in vitro by transformation of HLA-A*2402 or HLA-B*3501-expressing B cells using the standard 
EBV isolate B.95.8; and the EBV-transformed B-cell line LG2-EBV (HLA-A*24; -A*32; -B*35; -
B*44; kindly provided by Dr Pierre van der Bruggen Ludwig Institute for Cancer Research, 
Brussels, Belgium). 
All cell lines were cultured in RPMI-1640 (Gibco), containing 2 mM L-glutamine, 10% 
fetal bovine serum (Gibco), 100 μg/ml streptomycin and 100 IU/ml penicillin (Sigma), with the 
exception of LG2-EBV cell line, which was cultured in complete IMDM ([Lonza, Verviers, 
Belgium]) supplemented with 2 mM L-glutamine, 10% fetal bovine serum, 100 μg/ml 
streptomycin and 100 IU/ml penicillin). C1R-A3 cell line was kept in culture with the selective 
hygromycin (220μg/ml; Sigma) in order to express the HLA-A*0301 allele. 
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Bioinformatics tools, T-cell epitope mapping and peptide synthesis 
IGHV1-69 aminoacid (aa) sequences derived from the lymphoma cells of 55 CLL patients 
and 15 patients with HCV-related lymphoproliferations were kindly provided respectively by Dr 
Valter Gattei (Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento 
Oncologico, I.R.C.C.S., Aviano, PN, Italy) and Dr Gianluca Gaidano (Division of Hematology, 
Department of Clinical and Experimental Medicine, Amedeo Avogadro University of Eastern 
Piedmont, Novara, Italy), and by Dr Valli De Re (Experimental and Clinical Pharmacology, Centro 
di Riferimento Oncologico, National Cancer Institute, Aviano, Italy). Sequence comparison and 
alignment were performed through the bioinformatic MultAlin sequence alignment software 
(http://multalin.toulouse.inra.fr/multalin/) [113], generating a unique IGHV1-69 optimized 
sequence. 
Within a IGHV1-69 germline sequence derived from a patient affected by a HCV-
associated lymphoma and within the optimized IGHV1-69 sequence, 2 libraries of respectively 
112 and 87 overlapping 9-mers with 1 amino acid offset, spanning the entire sequence 
(PEPscreen, ProImmune, Oxford), were screened in HLA-binding assay. The binding affinity of 
each peptide to the HLA-A*0101, -A*0201, -A*0301, -A*2402, -B*0702, -B*0801, and -B*3501 
alleles, was evaluated through the REVEAL binding assay (ProImmune). This novel in vitro 
technology screens peptide libraries for their ability to stabilize the MHC complex. The 
approach measures the 'on-rate' and 'off-rate' of each peptide for the interested HLA allele 
investigating its binding kinetics.  In general, good T cell epitopes tend to have rapid on-rates 
and slow off-rates [114]. The assay assigns then to each peptide a score relative to a known T 
cell epitope that has a borderline affinity to the allele of interest and identifies the most 
immunogenic peptides. Finally, the peptide-MHC complexes with the highest binding affinity 
are selected for the synthesis of MHC class I-peptide pentamer complexes (ProVE
TM
 pentamers; 
ProImmune) for epitope validation. 
The probability of proteasomal processing was assessed for the first and the last aa 
residues of each predicted epitope, with NETchop, a predictor of proteasomal processing based 
upon a neural network (http://www.cbs.dtu.dk/services/NetChop/) [115]. The MHC affinity of 
IGHV1-69 epitopes was investigated through 3 different bioinformatics software: Syfpeithi 
(www.syfpeithi.de) [116], Bimas (www-bimas.cit.nih.gov/molbio/hla_bind/) [117], and NetMHC 
(www.cbs.dtu.dk/services/NetMHC/) [118]. 
The following virus-derived peptides were used as positive controls: HLA-A*0201-
restricted Flu matrix 1 M158-66 peptide (GILGFVFTL), -A*0301-restricted EBV EBNA3A-RLR603-611 
(RLRAEAQYK), -A*2402-restricted CMV pp65-QYD341-349 (QYDPVAALF), and –B*3501 CMV pp65-
IPS123-131 (IPSINVHHY). The HLA-A*0201-restricted MelanA/MART126-35 peptide analogue 
ELAGIGILTV was employed as TAA positive control in the generation of peptide-specific 
cytotoxic T lymphocytes. Selected IGHV1-69-derived peptides (ASG22-30, RSE85-93, QLV3-11, GTA54-
62, EWM44-52, EVK8-16, IPI50-58, TAY76-84) together with the positive controls were synthesized by 
fluorenylmethoxycarbonil synthesis (Primm, Milan, Italy), purity (>95%) was determined by 
reverse-phase high-performance liquid chromatography and verified by mass spectral MALDI-
TOF analysis. Peptides were dissolved in DMSO at a concentration of 5 mg/ml and stored at -
80°C until use. Work stocks for each peptide were prepared in phosphate-buffered saline (PBS; 
Biomerieux, Marcy l’Etoile, France) at a final concentration of 500μg/ml and stored frozen. 
IGHV1-69 (QLV3-11, EWM44-52, IPI50-58), viral (Flu M1-GIL58-66, EBV BRLF1-YVL109-117, EBV EBNA3A-
RLR603-611, EBV BRLF1-TYP198-206, CMV pp65-QYD341-349, CMV pp65-IPS123-131), and control (HIV 
Pol-PMD908-916, human NNMT-QLL70-79, human NNMT-YYM203-211, human DDX-TPV688-696) 
peptides were kindly synthesized by Prof Stefan Stefanović group (Department of Immunology, 
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University of Tübingen, Tübingen, Germany), dissolved in DMSO at a concentration of 1 mg/ml 
with distilled water and 10% DMSO, and stored at -80°C until use. 
Monomers refolding and Multimers production 
MHC class-I/peptide monomers were refolded and biotinylated using standards 
protocols [103,119]. Specifically, HLA-heavy chain inclusion bodies (kindly provided by Dr Cécile 
Gouttefangeas, Department of Immunology, University of Tübingen, Tübingen, Germany), 
diluted in Urea buffer (8M Urea [UCB], 10mM Tris pH 8 [Sigma], 100mM NaH2PO4 [Merk], 0.1 
mM EDTA [Roth], 0.1 mM DTT) 20mg/ml, together with MHC-light chain inclusion bodies were 
supplemented with injection buffer (3M guanidine HCl [Fluka], 10mM NaAcetate [Sigma], 
10mM EDTA [Sigma], pH4.2). Both were added to 250ml of refolding buffer (L-Arginine base 
[Fluka], HEPES [Roth], EDTA [Sigma] in ddH2O, pH 7.76), supplemented with reduced 
glutathione, oxidised glutathione, PMSF (phenylmethanesulfonylfluoride, Sigma), and 2.5-
7.5mg of the selected peptide diluted 10mg/ml in DMSO. The reaction was then incubated 
overnight at 10°C while gently shaking. The 2° day heavy chain was added twice every 12h.  
At day 3 the reaction was filtered through 0.22μm vacuum filter and concentrated to 
25ml at 60psi in an Assemble Amicon stirred cell (Fisher Scientific). Retentate was taken apart 
at 4°C till day 5, while MHC heavy chain and MHC light chain were added together with PMSF to 
the permeate. Heavy chain was appended other 2 times every 12 hours.  
At day 6 the reaction was filtered again and concentrated till 25ml, added to the 
concentrate of day 3 and spinned at 3200g for 10 min. The obtained supernatant was further 
concentrated using the Amicon Ultra-15 devise (Millipore) until obtaining 5ml of retentate. 
After spinning the retentate at 3200g for 10 min, the supernatant was used to do a size 
exclusion chromatography (Fast protein liquid chromatography, FPLC) on a S75 column using 
TBS (20mM Tris [Sigma] pH 8.0, 150mM NaCl [Merck], 0.5% Sodium azide [Sigma]) as buffer. 
Five ml fractions were stored through the FPLC and the UV absorption at 280nm was recorded. 
Fractions correspondent to the monomer peak were collected and immediately supplemented 
with PMSF, Leupeptin (100μg/ml, Roche) and Pepstatin (70μg/ml, Roche). The reaction was 
then gradually concentrated with the Amicon Ultra-15 devise till having 5 ml of retentate. 
Afterwards, the collected monomer was biotinylated adding Tris (80mM) pH 8, MgCl2 (5mM), 
ATP (5mM), BirA enzyme (Affinity) and D-Biotin (0.6mM; Sigma), and incubated 16h at 27°C. 
Finally, the biotinylated monomer was centrifuged at 3200 g for 5 min and employed in 
another FPLC separation on the S75 column as described above. The biotinylated monomer 
peak was collected and immediately supplemented with PMSF, leupeptin and pepstatin, 
together with sodium azide 0.1% and EDTA 2mM. The reaction was further concentrated with 
the Amicon Ultra-15 devise till about 500μl. Protein concentration was evaluated through 
Bradford assay and adjusted to 2.0mg/ml with permeate. Monomer aliquots were stored at -
80°C until use. 
Peptide sequence in the refolded monomer was verified with mass spectral MALDI-TOF 
analysis (kindly performed by Claudia Falkenburger, Department of Immunology, University of 
Tübingen, Tübingen, Germany). 
Monomers were tetramerized adding the appropriate volume of Streptavidin-
Phycoerythrin (PE; 159μg for 100μg monomer; Invitrogen, Molecular Probes) or Streptavidin-
Allophycocyanin (APC; 87μg for 100μg monomer; Invitrogen, Molecular Probes) in 10 times 
every 30 min. To store labelled-tetramers, a freezing solution (containing 16% glycerol) was 
added to the tetramer, and aliquots were kept at -80°C till use. 
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In addition to the tetramers, PE-labelled Pro5® Pentamers were synthesized by 
ProImmune for selected epitopes (HLA-A*0201 QLV3-11, HLA-A*2402 EWM44-52, and HLA-
B*3501 IPI50-58), after epitope validation studies done with unlabelled ProVE
TM
 Pentamers. PE-
labelled HLA-A*0201-MelanA/MART126-35, -A*0201-Flu M1-GIL58-66, -A*2402-CMV pp65-QYD341-
349, and –B*3501 CMV pp65-IPS123-131 pentamers were also purchased from ProImmune.  
Multimer and intracellular staining in flow cytometry 
IGHV1-69-specific ProVE
TM
 and Pro5® pentamers were tested ex vivo on patients’ and 
healthy donors’ PBMCs. Peptide-specific CTLs cultures were analysed with both, IGHV1-69-
specific tetramers and pentamers. The following fluorescent-conjugated monoclonal antibodies 
were combined with multimers in order to better characterized epitope-specific T cells: α-CD4 
phycoerythrin-cyanine5 (PeCy5; mouse IgG1, 13B8.2), α-CD8 phycoerythrin-cyanine7 (PeCy7; 
mouse IgG1, SFCI2IThy2D3), α-CD19 fluorescein isothiocyanate (FITC, mouse IgG1 k, J3-119), 
and α-CD45RA ECD (PE-Texas Red, mouse IgG1, 2H4LDH11LDB9) all from Beckman Coulter 
(Fullerton, CA, USA); α-CD4 FITC (mouse IgG1, RPA-T4), α-CD4 APC-Cy7 (mouse IgG1, RPA-T4), 
α-CD8 Peridinin chlorophyll (PerCP, mouse IgG1, SK1), α-CD8-APC (mouse IgG1, RPA-T8), α-
CD19-FITC (mouse IgG1, HIB19), α-CD107a FITC (mouse IgG1, H4A3), α-CD197 PE (CCR7, rat 
IgG2a k, 3D12), α-IFNγ PeCy7 (mouse IgG1, 4S.B3), α-IL2 APC (rat IgG2a, MQ1-17H12) 
purchased from BD Biosciences (Becton Dickinson, Franklin Lakes, NJ, USA); α-TNFα PacificBlue 
(mouse IgG1, MAb11) from BioLegend (San Diego, CA, USA); α-CD8-FITC (OKT8) was kindly 
provided by Dr Cécile Gouttefangeas  (Department of Immunology, University of Tübingen, 
Tübingen, Germany), together with PE- and APC-labelled Flu (HLA-A*0201-restricted, M158-66-
specific), EBV (HLA-A*0201-restricted, BRLF1109-117-specific) and CMV (HLA-A*2402-restricted, 
pp65341-349-specific) specific tetramers. Properly labelled isotypic antibodies were used as 
negative controls. 
Pentamer staining was performed under manufacture’s instructions, with a variation in 
the reagent volume and the staining time. Briefly, pentamer vial was centrifuged at 14,000g for 
5 min, to avoid the collection of protein aggregates. Then, 15 μl of pentamer were added to the 
cells (1-2x10
6
 PBMCs, or 5x10
5
 CTLs) in 50μl of wash buffer (PBS) for 15 min at room 
temperature. Finally, without washing, optimal amounts (1μg/1x10
6
 cells) of surface antibodies 
were added to the sample for 30 min at 4°C. All antibodies were used in an appropriate volume 
of 10% rabbit serum (Dako, Glosdrup, Denmark) and PBS to reduce unspecific signal. After 2 
washes in PBS, cells were then re-suspended in a fixing solution (1% Paraformaldehyd in PBS) 
and read at the flow cytometer. Cytofluorimetric analysis was performed with a FACSCalibur 
(Becton Dickinson) and a Cytomics FC500 (Beckman Coulter, Fullerton, CA) and at least 1 x 10
6
 
events were acquired. Obtained data were analyzed with CXP software (Beckman Coulter, 
Fullerton, CA, USA) and WinMDI 2.9 software (Windows Multiple Document Interafce for Flow 
Cytometry, Microsoft). 
Tetramers were employed as follow: cells were washed twice with FACS-Washing buffer 
(PBS with 0.01% sodium azide, 2mM EDTA and 2% FCS) and stained with 5μg/ml or 2.5μg/ml of 
the correspondent tetramer. Tetramer mix was prepared in staining buffer (PBS with 50% FCS, 
2mM EDTA and 0.02% sodium azide) and centrifuged at 14,000g for 5min at 4°C to eliminate 
possible aggregates. Fifty μl of this solution were added to the cells, which were then incubated 
for 15 min at room temperature. Without washing, an appropriate volume of surface 
antibodies was then added to the cells in 20μl of FACS washing buffer, together with the 
viability control AquaLive/Dead® Reagent (LifeTechnologies), and incubated 20min at 4°C. Cells 
were hence washed and re-suspended in FACS-Washing buffer for the analysis or permeabilized 
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with Cytoperm/Cytofix Reagent (Becton Dickinson) for 20min at 4°C. After a further washing 
step in Permwash buffer (PBS with 0.02% sodium azide, 0.5% BSA [Sigma], and 0.1% Saponin 
[Sigma]), permeabilized cells were stained for intracellular marker detection in 50μl of 
Permwash buffer, and incubated 20min at 4°C. Finally, samples were washed twice in 
Permwash buffer and re-suspended in FACS-Washing buffer for the analysis. Cytofluorimetric 
analysis was performed with a BD FACS Canto II flow cytometer (Becton Dickinson) equipped 
with the DIVA software, and all cells were acquired for each sample. Data analysis was carried 
out with FlowJo software (Tree Star, Ashland, OR). 
IFN-γ ELISPOT assays 
The interferon (IFN)-γ release enzyme-linked immunosorbent spot (ELISPOT) assay was 
performed using a commercial kit (Human IFN gamma ELISPOT; Thermo scientific, Rockford, IL, 
USA), according to manufacturer’s instructions. The assay was carried out employing purified 
effector T cells, obtained by immunomagnetic enrichment protocols using the human T cell 
isolation kit II (Miltenyi Biotec, Bergisch Gladbach, Germany) under manufacture’s instructions, 
and collecting the non-T cell fraction (mainly B cells and monocytes), which was used as a 
source of antigen presenting cells (APCs). Ten thousand APCs were seeded in each well of the 
ELISPOT plate, loaded with 10 μg/ml of 9-mer peptide in complete RPMI medium, and 
incubated for two hours at 37°C with 5% CO2. Purified effectors were then added to peptide-
loaded APCs (50,000 cells/well) at a 5:1 effector:target ratio. APCs stimulated with viral 
peptides and unrelated peptides (derived from simian virus 40) were used as positive and 
negative controls, respectively. Finally, some wells were stimulated with phytohaemagglutinin 
(PHA) to value T-cell functionality. Cells were seeded onto ELISPOT capture plates in triplicates 
and incubated for 24 hours at 37°C with 5% CO2. All plates were evaluated by a computer-
assisted ELISPOT reader (Eli.Expert, A.EL.VIS GmbH, Hannover, Germany). Responses were 
considered significant if a minimum of 5 IFN-γ producing cells were detected in the wells, and 
data were indicated as IFN-γ Spot Forming Cells (SFC). 
Generation and characterization of peptide-specific CTLs 
Several CTLs generation protocols were tested in this study in order to improve the yield 
of peptide-stimulated T cells and to select the most appropriate scheme to induce epitope-
specific T cells also from lymphoma patients’ PBMCs samples. 
Stimulation with autologous monocytes-derived dendritic cells 
Healthy donors’ purified PBMCs were re-suspended in serum-free medium and 
incubated at 37°C to allow for plastic-adherent step. After 1 h and 30 min, non-adherent 
peripheral blood lymphocytes (PBLs) were removed and vitally cryopreserved, while immature 
dendritic cells (DC) were obtained by culture adherent monocytes in complete RPMI 1640 
supplemented with 10% of heat-inactivated healthy donors’ serum, recombinant human GM-
CSF (50ng/ml; R&D Systems, Abingdon, UK) and IL-4 (25ng/ml, R&D Systems, Abingdon, UK). 
Cells were substituted with 50% of fresh medium and cytokines concentrations were re-
established on day 3 and day 6. On day 6, DC maturation was induced with lipopolysaccharide 
(LPS; 1.5μg/ml) from Salmonella Typhimurium (Sigma). After over-night incubation at 37°C, 10
6
 
mature DC/ml were seeded in 48-wells plates, pulsed with IGHV1-69- or viral-derived peptides 
(25μg/ml), and then incubated for 2 hours at 37°C in 5% CO2. Peptide-pulsed DC were re-
suspended in complete medium, supplemented with recombinant human IL-7 (rhIL7; 20ng/ml, 
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R&D Systems) and co-cultured in 48-wells plates with 10
6
/ml autologous PBLs, cryopreserved 
on day 1, at a 20:1 effector:target ratio. Recombinant human IL-2 (rhIL2; 3ng/ml; R&D Systems) 
was added on day 3. 
The CTLs cultures were re-stimulated twice every 7 days with freshly prepared peptide-
pulsed-DC added at a ratio of 20:1 CTLs:DCs. Other 2 more re-stimulations were performed 
using autologous PBMCs pulsed with 100μg/ml peptide for 2h, γ–irradiated with 30 Gray (Gy), 
and added at a ratio of 10:1 (CTLs:PBMCs) to the CTLs culture. Alternatively, T2-A2 or 
heterologous HLA-matched LCLs were used as stimulators. One million cells/ml were pulsed 
with 20μg/ml of the correspondent peptide for 2h, then γ-irradiated with 60 Gy (T2-A2) or 30 
Gy (LCLs), and finally added to the CTLs at a ratio of 10:1 CTLs:stimulators. RhIL7 (20ng/ml) was 
added at each stimulation, while medium was supplemented with rhIL2 (3ng/ml final 
concentration) 3 days after the stimulation, and then every 3 days. 
CTLs cultures were characterized in flow cytometry for their memory phenotype before 
each re-stimulation and their specificity was evaluated 1 week after the last re-stimulation in a 
cytotoxic assay, or with pentamer staining after further 5 days in medium without cytokines 
and 2h in ice, to promote TCR expression. 
Stimulation with peptide-loaded HLA-matched cell lines 
An alternative protocol was used to compare the ability to induce epitope-specific CTLs 
in healthy donors’ and patients’ PBMCs [101,120]. T2-A2, C1R-A3 or HLA-matched LCLs were 
stimulated with different concentrations of IGHV1-69-derived peptides (0.1μg/ml, 1μg/ml, 
10μg/ml) in complete medium, for 2h at 37°C and 5% CO2, and then γ-irradiated with 30Gy. 
Empty targets and targets stimulated with HLA-matched viral-derived peptides (5μg/ml) were 
used respectively as negative and positive induction controls. Healthy donors’ and patients’ 
PBLs, obtained after monocytes depletion with plastic-adherent step, were cultivated in 
medium with 10% heat-inactivated human serum, seeded 10
6
/ml in 48-wells plates, and 
stimulators were added at a 4:1 (effectors:stimulators) ratio. At day 3, and every 3 days, 
cultures were supplemented with rhIL-2 (3ng/ml). Weekly re-stimulations were performed with 
peptide-pulsed cell lines as at day 1, stimulating CTLs cultures with a ratio of 2:1 
CTLs:stimulators. After the 3° and the 4° stimulations, CTLs cultures were characterized for their 
memory phenotype in flow cytometry, and tested for their specificity in cytotoxic assays and 
with pentamer staining. 
Stimulation with artificial antigen presenting cells 
Finally, we tested a protocol employing synthetic artificial APC (aAPC) developed to elicit 
and expand also low-avidity tumor-directed human CTL lines [119]. PBMCs were freshly 
isolated from a healthy donor’s leukapheresis, by Ficoll-Hypaque gradient using standard 
procedures. CD8
+
 T cells were purified using CD8 Microbeads (Miltenyi Biotec, Bergisch 
Gladbach, Germany), staining up to 250x10
6
 cells with 300μl beads in 1200μl MACS buffer (PBS, 
0.5% BSA, 2mM EDTA) and collecting the fraction linked to the MACS column (Miltenyi Biotec, 
Bergisch Gladbach, Germany). CD8
+
 purified T cells were maintained overnight in IMDM 
medium with 10% human serum (c.c. pro, Oberdorla, Germany) and 50 μM β–Mercaptoethanol 
(Roth, Karlsruhe, Germany), supplemented with 2.5ng/ml IL7 (Promokine, Heidelberg, 
Germany) and 10U/ml IL2 (Proleukin, Novartis, Basel, Switzerland), at 37°C and 7.5% CO2. 
Streptavidin Coated Microspheres (BangsLaboratories, Inc., USA) were loaded with the 
biotinylated anti-human CD28 antibody 9.3 [121] (kindly provided by Claudia Falkenburger, 
Department of Immunology, University of Tübingen, Tübingen, Germany), and the biotinylated 
IGHV1-69 correspondent monomer, the HLA-A*0201 DDX168-176 (used as negative control), or 
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the HLA-A*0201 BRLF1109-117 (used as positive control; both controls were kindly provided by Dr 
Cécile Gouttefangeas, Department of Immunology, University of Tübingen, Tübingen, Germany) 
monomers. aAPC were arranged accounting 200,000 beads, 150ng CD28 biotinylated mAb, and 
50ng monomer, for 1 stimulation of each well. Each monomer was tested in 24 different wells 
and cells were stimulated 3 times. 
After the overnight incubation, purified CD8
+
 T cells were harvested, counted, and 
seeded 10
6
 cells/well in 100μl T-cell complete medium, together with CD28/MHC loaded beads 
in the presence of IL12 (final concentration in the culture 5ng/ml; Promokine, Heidelberg, 
Germany), and incubated at 37°C with 7.5% CO2. At day 3 medium was changed and 
supplemented with IL2 (40U/ml). 
After 3 stimulations, the specificity of each well was evaluated in flow cytometry 
through tetramer staining (2.5μl/ml tetramer), blocking possible streptavidin-free binding sites 
with a previous incubation of 30 min at 4°C with 10μg/ml streptavidin (New England BioLabs 
GmbH, Frankfurt, Germany). 
Tetramer-positive cells isolation and cloning 
Tetramer-positive wells were re-stimulated once with aAPCs and after 10 days collected, 
stained with 2.5μg/ml of the correspondent PE-labeled tetramer and isolated with anti-PE 
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) under manufacture’s instructions. 
The positive fraction was eluted twice from the MACS column, while the negative fraction was 
kept in culture with 2.6U/ml IL2. Tetramer-positive purified cells were cultivated parallel 
100,000cells /well, 10cells/well, and 5cells/well in 96-wells plates, in T-cell medium with IL2 
(150UI/ml), IL7 (5ng/ml), and IL15 (5ng/ml; Promokine, Heidelberg, Germany). Every 2 weeks 
cells were stimulated with 1.5x10
5
/well freshly isolated PBMCs from 3 different healthy donors 
and γ-irradiated with 60Gy, and 0.15x10
5
/well LG2-EBV γ-irradiated with 200Gy. The bulk 
culture (100,000cells/well) was supplemented with 0.1μg/ml of the correspondent peptide, 
while the clones (10cells/well and 5cells/well) were stimulated with 1μg/ml PHA. The specificity 
of bulk and clones were finally analyzed with tetramer and intracellular staining after peptide 
stimulation. 
Cytotoxicity assays 
Cytotoxic activity of peptide-specific CTLs was evaluated in a Calcein–AM release assay 
using peptide-pulsed T2-A2, C1R-A3, or heterologous HLA-A*2402- or HLA-B*3501-expressing 
LCLs as targets. Target cells (1x10
6
) were resuspended in 0.5 ml RPMI with 10% human serum, 
and pulsed with 20 μg/ml of corresponding peptide for 2 hours at 37°C and 5% CO2. After 
washing, cells were diluted 1x10
6
/ml in Hanks Balanced Salt Solution without phenol red 
(HBSS), supplemented with 10 % FCS, labelled with 8 μM of Calcein-AM (Calbiochem, San 
Diego, CA) and incubated 1 h and 30 min at 37°C and 5% CO2. Empty targets, the IGHV1-69
+
 PG 
B.95.8, and the NK-sensitive erythroleukemia K562 cell lines were also included in the cytotoxic 
assays, staining them with Calcein-AM as the peptide-pulsed targets. Labeled cells were washed 
three times, counted, and seeded in 96-wells plate at a concentration of 5x10
3
 cells/50 μl/well. 
One half of so prepared target cells were incubated with 1μg/1x10
6
 cells anti-MHC class-I 
W6/32 antibody (Abcam, Cambridge, MA) 30 min at room temperature, washed and re-
suspended 5x10
3
 cells/50 μl/well, to assess the HLA-class I restriction of CTL responses. 
Unlabeled K562 were eventually added in each well (5x10
3
 cells/50 μl/well) to reduce un-
specific cytotoxicity signal. CTLs were added at 20:1, 10:1, 5:1, and 2.5:1 effector:target ratio. 
All tests were performed in triplicate. To obtain total calcein-releasing cells, targets were 
incubated with 100μl/well of lysis buffer (25 mM sodium borate, 0.1% Triton-X100 in HBSS, pH 
9.0). While spontaneous release was determined by seeding target cells and adding 100μl/well 
MATERIALS AND METHODS_____________________________________________________ 
 40 
HBSS. Plates were centrifuged and incubated 4 h at 37°C and 5% CO2 in a final volume of 
200μl/well. Following incubation, the content of each well was mixed, plates were centrifuged 
and 100μl of the supernatant was transferred to a 96-well black culture plate. Fluorescence 
intensity was measured by reading the plates from the top using a SpectraFluorPlus (Tecan, 
Austria). Excitation and emission filters were 485 and 535 nm, respectively and gain was set at 
70. The percentage of lysis was calculated as follows: 
 
Lysis % = Experimental release - Spontaneous release x 100 
Total release - Spontaneous release 
Statistical analysis 
Data obtained from multiple independent experiments were expressed as mean and 
standard deviation for immunophenotypic analysis of peptide-specific PBMCs and CTLs 
cultures. Percentage of specific lysis in cytotoxic assays was indicated as mean of triplicates 
obtained in the same experiment. The Student’s t test for two tailed distributions was used for 
the statistical analysis of ex vivo pentamer staining and IFN-γ ELISPOT assays to compare data 
obtained from patients’ samples with results achieved on healthy donors’ cells. Data were 
considered to be statistically significant when P≤0.05 (two-sided). 
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RESULTS 
Outline of the study 
The main purpose of this study was the investigation of IGHV1-69 eligibility as a 
promising candidate for the development of an immunotherapeutic approach designed for a 
subset of patients affected by lymphoproliferations sharing similar Id proteins. 
On these assumptions, we first compared IGHV1-69 sequences derived from B-NHL 
patients in order to design an optimized sequence with the highest degree of similarity among 
the selected variants. Within this sequence, we identified the most immunogenic epitopes in 
the 7 HLA class-I restrictions most frequent in the Caucasian population [122], and synthesized 
the correspondent PE-labeled pentamers and tetramers. 
Since the immunogenicity of a TAA depends also on its ability to induce specific host 
immune responses, T-cell memory responses against IGHV1-69 were investigated in IGHV1-69
+
 
B-NHL patients and in individuals affected by an IGHV1-69
+
 lymphoproliferation with the newly 
synthesized multimers. IGHV1-69-specific T-cell responses were then characterized for their 
memory phenotype in flow cytometry and for their ability to secrete IFN-γ in ELISPOT assays. 
Finally, considering that a good candidate for an anti-tumor vaccination should be able 
to boost the specific immune responses naturally developed, CD8
+
 T-cells specific for IGHV1-69-
derived epitopes were expanded in vitro from both healthy donors’ and patients’ PBMCs using 
several protocols for the in vitro boosting of epitope-specific T-cell responses. The specificity of 
the CTLs lines obtained with these approaches was tested in flow cytometry with epitope-
specific multimers, and in cytotoxicity assays. 
Lastly, we also investigated the ability of IGHV1-69 to induce cross-reactive responses 
against targets expressing molecularly related Id, in order to validate the eligibility of IGHV1-69 
as a target for a subset-specific immunotherapy. For this purpose, we included as target in 
cytotoxicity assays a cell line derived from the lymphoma B-cells of an IGHV1-69
+
 CLL patient, 
and sharing the same HLA alleles with the selected CTLs lines. 
The thorough characterization of IGHV1-69 immunogenicity will provide a solid rational 
background for further in vivo studies aimed at verifying whether the optimized IGHV1-69 can 
function as a good candidate for a shared immunotherapy for a subset of patients carrying 
different lymphoproliferations expressing not only IGHV1-69, but also molecularly related Ids. 
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Patients’ characteristics 
Twenty-three patients carrying an IGHV1-69-expressing B-cell lymphoproliferation were 
included in this study. We collected samples from patients suffering from different diseases, 
including pre-malignant lymphoproliferations associated with HCV infection or autoimmunity, 
HCV- or autoimmunity-related lymphomas, CLL and follicular lymphomas (Table 1). All these 
disorders were selected on the basis of the shared expression of IGHV1-69 by clonal B cells and 
relevant HLA class I alleles of the patients. 
 
Patient 
number 
Disease HLA class I genotyping 
#1 Type II Mixed Cryoglobulinemia (HCV+) -A*2402, -B*3501 
#2 Type II Mixed Cryoglobulinemia -A*0301 
#3 Type III Mixed Cryoglobulinemia, Sjögren's Syndrome, Parotid MALT 
Lymphoma 
-A*0201 
#4 Type III Mixed Cryoglobulinemia, Sjögren's Syndrome (HCV+) -A*2402, -B*0801, -B*3501 
#5 Type II Mixed Cryoglobulinemia (HCV+) -A*2402 
#6 Mantle Cell Lymphoma (HCV+) -A*0201, -B*3501 
#7 Chronic Lymphocytic Leukaemia -A*0201, -A*0301 
#8 Chronic Lymphocytic Leukaemia -A*0201, -A*2402 
#9 Chronic Lymphocytic Leukaemia -A*0201, -A*2402 
#10 Chronic Lymphocytic Leukaemia -A*2402, -B*3501 
#11 Chronic Lymphocytic Leukaemia -A*0101, -A*0201 
#12 Chronic Lymphocytic Leukaemia -A*0301 
#13 Chronic Lymphocytic Leukaemia -A*0301, -A*2402 
#14 Chronic Lymphocytic Leukaemia -A*0201, -A*0301, -B*3501 
#15 Chronic Lymphocytic Leukaemia -A*0201, -B*3501 
#16 Chronic Lymphocytic Leukaemia -A*0101, -A*2402, -B*0702, -B*3501 
#17 Type II Mixed Cryoglobulinemia (HBV+, HCV+) -A*2402, -B*0702 
#18 Chronic Lymphocytic Leukaemia -A*0301 
#19 Non Germinal Center Diffuse Large B-Cell Lymphoma -A*0301, -A*2402 
#20 Burkitt Lymphoma -A*0201, -B*3501 
#21 Mediastinal Large B-Cell Lymphoma -A*0201 
#22 Follicular G1-2 Lymphoma -A*0201 
#23 Plasmablastic Lymphoma (HHV8+) -A*0201, -B*3501 
Table 1. Patients’ clinical-pathological characteristics and HLA class-I genotyping. The presence of infection by HCV 
(or HBV, or HHV8) is indicated in brackets. MALT: Mucosa-Associated Lymphoid Tissue 
Optimization of the IGHV1-69 sequence 
One of the main limitations of current Id vaccinations is the individual feature of the 
vaccine target. In order to bypass the uniqueness of each Ids, we selected a shared Id protein, 
IGHV1-69, whose expression was documented in several B-NHL and pre-malignant 
lymphoproliferations [28,58,60,61,71,77,81]. To further improve the immunogenic features of 
IGHV1-69 as shared antigen, we compared the predicted IGHV1-69 aminoacid sequences 
derived from 55 CLL patients and from 15 individuals with HCV- or autoimmunity-related 
lymphoproliferations. The alignment of these 70 aa sequences resulted in a single “consensus 
sequence”, which was deprived of the hypervariable CDR3 region, to achieve the highest 
degree of similarity among the selected IGHV1-69 variants. For each position we selected the 
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most represented aminoacid among the collected sequences, and obtained an optimized 
sequence characterized by a homology degree >80% with the IGHV1-69 reference germ line 
sequence (derived from a HCV-related lymphoma). Moreover, analysing the germ line sequence 
with bioinformatics engines for the prediction of MHC affinity (Syfpeithi, Bimas and NetMHC), 
we identified the most immunogenic epitope candidates in the context of the 7 most common 
HLA class-I alleles of the Caucasian population (-A*0101, -A*0201, -A*0301, -A*2402, -B*0702, -
B*0801, and -B*3501) [122], and we maintained unchanged the corresponding aa residues in 
the final sequence. Using this approach, we selected the most immunogenic regions, and 
obtained an IGHV1-69 new variant, optimized for the extent of similarity and predicted 
immunogenic features (Figure 9).  
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Patent pending
 
Figure 9. Sequence alignment and design of the IGHV1-69 optimized sequence. IGHV1-69 sequences are compared to the aa sequence of a reference germ line IGHV1-69 
segment derived from a HCV-associated lymphoma. The 100% homology on the aa level with the germ line sequence is indicated by a dot, while a change of the aa residue is 
underlined with capital letters. 
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Identification and validation of potential CTLs epitopes within IGHV1-69 
sequences 
Through the REVEAL binding assay (ProImmune) [123,124], we investigated the binding 
affinity to HLA molecules of 9-aa peptides derived from an IGHV1-69 sequence (obtained from 
a patient affected by a HCV-associated lymphoma), and the optimized IGHV1-69 sequence. We 
identified 28 peptides within the patient’s sequence and 13 in the optimized one, able to bind 1 
of the selected MHC allele products (HLA-A*0101, -A*0201, -A*0301, -A*2402, -B*0702, -
B*0801, -B*3501). 
Table 2 shows the aa sequence of each predicted epitope, the comparison between the 
patient’s sequence-derived peptides and their corresponding sequence in the optimized IGHV1-
69, and vice versa. 
 
HLA IGHV1-69 patient’s sequence IGHV1-69 optimized sequence Sequence comparison 
-A*0101 
LTSEDTAVY [89-97] 
GTDSSNYYY [102-110] 
DSSNYYYFY [104-112] 
 
 
 
 
ASGGTFSSY [24-32] 
RSEDTAVYY [87-95] 
LRSEDTAVY [86-94] no affinity 
CDR3 region, absent in the optimized IGHV1-69 
CDR3 region, absent in the optimized IGHV1-69 
 
ASGGTFSTS [27-35] no affinity  
TSEDTAVYF [90-98] no affinity 
-A*0201 
FSTSAISWV [32-40] 
SLTSEDTAV [88-96] 
 
 
 
QLVQSGAEV [3-11] 
FSSYAISWV [29-37] no affinity 
SLRSEDTAV [85-93] no affinity 
 
QLVQSGAEE [6-14] no affinity 
-A*0301 
LVQSGAEEK [7-15] 
GSAVKVSCK [18-26] 
KASGGTFST [26-34] 
STSAISWVR [33-41] 
GTANYAQKF [59-67] 
GTDSSNYYY [102-110] 
 
 
 
 
 
 
 
GTANYAQKF [56-64] 
LVQSGAEVK [4-12] no affinity 
GSSVKVSCK [15-23] no affinity 
KASGGTFSS [23-31] no affinity 
SSYAISWVR [30-38] no affinity 
GTANYAQKF [56-64] not changed 
CDR3 region, absent in the optimized IGHV1-69 
 
GTANYAQKF [59-67] not changed 
-A*2402 
TFSTSAISW [31-39] 
QWMGGIIPI [49-57] 
AYMELSSLT [82-90] 
SSNYYYFYW [105-113] 
 
 
 
 
 
GSSVKVSCK [15-23] 
GTFSSYAIS [27-35] 
EWMGGIIPI [46-54] 
TFSSYAISW [28-36] no affinity 
EWMGGIIPI [46-54] confirmed affinity 
AYMELSSLR [79-87] no affinity  
CDR3 region, absent in the optimized IGHV1-69 
 
GSAVKVSCK [18-26] no affinity 
GTFSTSAIS [30-38] no affinity 
QWMGGIIPI [49-57] confirmed affinity 
-B*0702 
QPAQVQLVQ [1-9] 
EEKRPGSAV [13-21] 
KRPGSAVKV [15-23] 
RPGSAVKVS [16-24] 
SCKASGGTF [24-32]  
AISWVRQAP [36-44] 
WVRQAPGQG [39-47] 
APGQGLQWM [43-51] 
 
 
 
 
 
 
 
 
 
EVKKPGSSV [10-18] 
SCKASGGTF [21-29] 
AISWVRQAP [33-41] 
WVRQAPGQG [36-44] 
Absent in the optimized IGHV1-69 
EVKKPGSSV [10-18] confirmed affinity 
KKPGSSVKV [12-20] no affinity 
KPGSSVKVS [13-21] no affinity 
SCKASGGTF [21-29] not changed 
AISWVRQAP [33-41] not changed 
WVRQAPGQG [36-44] not changed 
APGQGLEWM [40-48] no affinity 
 
EEKRPGSAV [13-21] confirmed affinity 
SCKASGGTF [24-32] not changed 
AISWVRQAP [36-44] not changed 
WVRQAPGQG [39-47] not changed 
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HLA IGHV1-69 germline sequence IGHV1-69 optimized sequence Sequence comparison 
-B*0801 None None  
-B*3501 
QPAQVQLVQ [1-9] 
IPIFGTANY [55-63] 
TAYMELSSL [81-89] 
LTSEDTAVY [89-97] 
DSSNYYYFY [104-112] 
 
 
 
 
 
 
IPIFGTANY [52-60] 
TAYMELSSL [78-86] 
Absent in the optimized IGHV1-69 
IPIFGTANY [52-60] not changed 
TAYMELSSL [78-86] not changed 
LRSEDTAVY [86-94] no affinity  
CDR3 region, absent in the optimized IGHV1-69 
 
IPIFGTANY [55-63] not changed 
TAYMELSSL [81-89] not changed 
Table 2. Potential HLA class-I restricted epitopes predicted through REVEAL binding assay in a patient-derived 
IGHV1-69 sequence and in the optimized one. [ ] indicate the aa positions of the first and the last residues of the 
nonamer in the source sequence. The comparison shows the corresponding peptide in the second sequence 
underling the differences in aa sequence and reporting the binding affinity results. 
As expected, sequence variations in the epitope anchor sites modified the binding 
affinity on the MHC allele [125], therefore, we did not identify the same epitopes in the 2 
sequences. However, most (8 out of 13) of the candidates found in the optimized IGHV1-69 
were present or confirmed also in the patient’s sequence. Conversely, since the optimized 
sequence was deprived of the CDR3 region, the potential epitopes (5 out of 23) detected in the 
CDR3 of the patient’s sequence, can not be considered as broadly usable candidates, because 
of the extremely variability observed among IGHV1-69 sequences in this region. 
We also compared the epitopes derived from the optimized IGHV1-69 sequence with 
several IGHV1-69 variants and with IGHV proteins belonging to the IGHV1 family. Interestingly, 
we observed that these epitopes are highly conserved not only in sequences derived from the 
same Id, but also in molecularly-related Ids (Table 3). 
 
HLA allele IGHV chain Peptide sequence HLA allele IGHV chain Peptide sequence 
HLA-A*0101 IGHV1-69 optim ASGGTFSSY HLA-A*0101 IGHV1-69 optim RSEDTAVYY 
 IGHV1-69*01 ASGGTFSSY  IGHV1-46*02 RSEDTAVYY 
 IGHV1-69*02 ASGGTFSSY  IGHV1-46*03 RSEDTAVYY 
 IGHV1-69*04 ASGGTFSSY  IGHV1-24*01 RSEDTAVYY 
 IGHV1-69*05 ASGGTFSSY  IGHV1-58*01 RSEDTAVYY 
 IGHV1-69*06 ASGGTFSSY  IGHV1-58*02 RSEDTAVYY 
 IGHV1-69*08 ASGGTFSSY HLA-A*0201 IGHV1-69 optim QLVQSGAEV 
 IGHV1-69*09 ASGGTFSSY  IGHV1-69*01 QLVQSGAEV 
 IGHV1-69*10 ASGGTFSSY  IGHV1-69*02 QLVQSGAEV 
 IGHV1-69*11 ASGGTFSSY  IGHV1-69*04 QLVQSGAEV 
 IGHV1-69*12 ASGGTFSSY  IGHV1-69*05 QLVQSGAEV 
 IGHV1-69*13 ASGGTFSSY  IGHV1-69*06 QLVQSGAEV 
 IGHV1-69*07 ASGGTFSSY  IGHV1-69*08 QLVQSGAEV 
HLA-A*0101 IGHV1-69 optim RSEDTAVYY   IGHV1-69*09  QLVQSGAEV 
 IGHV1-69*01 RSEDTAVYY  IGHV1-69*10 QLVQSGAEV 
 IGHV1-69*02 RSEDTAVYY  IGHV1-69*11 QLVQSGAEV 
 IGHV1-69*04 RSEDTAVYY  IGHV1-69*12 QLVQSGAEV 
 IGHV1-69*05 RSEDTAVYY  IGHV1-69*13 QLVQSGAEV 
 IGHV1-69*06 RSEDTAVYY  IGHV1-18*01 QLVQSGAEV 
 IGHV1-69*08 RSEDTAVYY  IGHV1-18*02 QLVQSGAEV 
 IGHV1-69*09 RSEDTAVYY  IGHV1-2*01 QLVQSGAEV 
 IGHV1-69*10 RSEDTAVYY  IGHV1-2*02 QLVQSGAEV 
 IGHV1-69*11 RSEDTAVYY  IGHV1-2*03 QLVQSGAEV 
 IGHV1-69*12 RSEDTAVYY  IGHV1-2*04 QLVQSGAEV 
 IGHV1-69*13 RSEDTAVYY  IGHV1-3*01 QLVQSGAEV 
 IGHV1-46*01 RSEDTAVYY  IGHV1-3*02 QLVQSGAEV 
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HLA allele IGHV chain Peptide sequence HLA allele IGHV chain Peptide sequence 
HLA-A*0201 IGHV1-69 optim QLVQSGAEV HLA-A*2402 IGHV1-69 optim GSSVKVSCK 
 IGHV1-46*01 QLVQSGAEV  IGHV1-46*02 GASVKVSCK 
 IGHV1-46*02 QLVQSGAEV  IGHV1-46*03 GASVKVSCK 
 IGHV1-46*03 QLVQSGAEV  IGHV1-58*01 GASVKVSCK 
 IGHV1-12*01 QLVQSGAEV  IGHV1-58*02 GASVKVSCK 
 IGHV1-12*02 QLVQSGAEV  IGHV1-24*01 GASVKVSCK 
 IGHV5-51*01 QLVQSGAEV  IGHV1-68*01 GASVKVSCK 
 IGHV5-51*02 QLVQSGAEV  IGHV1-12*01 GASVKVSCK 
 IGHV5-51*03 QLVQSGAEV  IGHV1-67*01 GASVKVSCK 
 IGHV5-51*04 QLVQSGAEV  IGHV7-4-1*01 GASVKVSCK 
 IGHV5-a*01 QLVQSGAEV  IGHV7-4-1*02 GASVKVSCK 
 IGHV5-a*02 QLVQSGAEV  IGHV7-81*01 GASVKVSCK 
 IGHV5-a*03 QLVQSGAEV  IGHV7-NL1*01 GASVKVSCK 
  IGHV5-a*04  QLVQSGAEV   IGHV7-4-1*03  GASVKVSCK 
 IGHV1-67*01 QLVQSGADV HLA-A*2402 IGHV1-69 optim GTFSSYAIS 
HLA-A*0301 IGHV1-69 optim GTANYAQKF  IGHV1-69*01 GTFSSYAIS 
 IGHV1-69*01 GTANYAQKF  IGHV1-69*03 GTFSSYAIS 
 IGHV1-69*03 GTANYAQKF  IGHV1-69*04 GTFSSYAIS 
 IGHV1-69*05 GTANYAQKF  IGHV1-69*05 GTFSSYAIS 
 IGHV1-69*06 GTANYAQKF  IGHV1-69*06 GTFSSYAIS 
 IGHV1-69*07 GTANYAQKF  IGHV1-69*07 GTFSSYAIS 
 IGHV1-69*10 GTANYAQKF  IGHV1-69*09 GTFSSYAIS 
 IGHV1-69*12 GTANYAQKF  IGHV1-69*10 GTFSSYAIS 
 IGHV1-69*13 GTANYAQKF  IGHV1-69*11 GTFSSYAIS 
 IGHV1-69*01 GTANYAQKF  IGHV1-69*12 GTFSSYAIS 
 IGHV1-69*03 GTANYAQKF  IGHV1-69*13 GTFSSYAIS 
HLA-A*2402 IGHV1-69 optim EWMGGIIPI HLA-B*0702 IGHV1-69 optim EVKKPGSSV 
 IGHV1-69*01 EWMGGIIPI  IGHV1-69*01 EVKKPGSSV 
 IGHV1-69*03 EWMGGIIPI  IGHV1-69*02 EVKKPGSSV 
 IGHV1-69*05 EWMGGIIPI  IGHV1-69*04 EVKKPGSSV 
 IGHV1-69*06 EWMGGIIPI  IGHV1-69*05 EVKKPGSSV 
 IGHV1-69*07 EWMGGIIPI  IGHV1-69*06 EVKKPGSSV 
 IGHV1-69*10 EWMGGIIPI  IGHV1-69*08 EVKKPGSSV 
 IGHV1-69*12 EWMGGIIPI  IGHV1-69*09 EVKKPGSSV 
 IGHV1-69*13 EWMGGIIPI  IGHV1-69*10 EVKKPGSSV 
HLA-A*2402 IGHV1-69 optim GSSVKVSCK  IGHV1-69*11 EVKKPGSSV 
 IGHV1-69*01 GSSVKVSCK  IGHV1-69*12 EVKKPGSSV 
 IGHV1-69*02 GSSVKVSCK  IGHV1-69*13 EVKKPGSSV 
 IGHV1-69*03 GSSVKVSCK  IGHV1-45*01 EVKKPGSSV 
 IGHV1-69*04 GSSVKVSCK  IGHV1-45*02 EVKKPGSSV 
 IGHV1-69*05 GSSVKVSCK  IGHV1-18*01 EVKKPGSSA 
 IGHV1-69*06 GSSVKVSCK  IGHV1-18*02 EVKKPGSSA 
 IGHV1-69*08 GSSVKVSCK  IGHV1-2*01 EVKKPGSSA 
 IGHV1-69*09 GSSVKVSCK  IGHV1-2*02 EVKKPGSSA 
 IGHV1-69*10 GSSVKVSCK  IGHV1-2*04 EVKKPGSSA 
 IGHV1-69*11 GSSVKVSCK  IGHV1-3*01 EVKKPGSSA 
 IGHV1-69*12 GSSVKVSCK  IGHV1-3*02 EVKKPGSSA 
 IGHV1-69*13 GSSVKVSCK  IGHV1-46*01 EVKKPGSSA 
 IGHV1-45*01 GSSVKVSCK  IGHV1-46*02 EVKKPGSSA 
 IGHV1-45*02 GSSVKVSCK  IGHV1-46*03 EVKKPGSSA 
 IGHV1-45*03 GSSVKVSCK  IGHV1-12*01 EVKKPGSSA 
 IGHV1-18*01 GASVKVSCK  IGHV1-12*02 EVKKPGSSA 
 IGHV1-18*02 GASVKVSCK  IGHV1-17*01 EVKKPGSAV 
 IGHV1-2*01 GASVKVSCK  IGHV1-17*02 EVKKPGSAV 
 IGHV1-2*02 GASVKVSCK  IGHV1-58*01 EVKKPGSST 
 IGHV1-2*03 GASVKVSCK  IGHV1-58*02 EVKKPGSST 
 IGHV1-2*04 GASVKVSCK HLA-B*0702 IGHV1-69 optim SCKASGGTF 
 IGHV1-3*01 GASVKVSCK  IGHV1-69*07 SCKASGGTF 
 IGHV1-3*02 GASVKVSCK  IGHV1-69*01 SCKASGGTF 
 IGHV1-46*01 GASVKVSCK  IGHV1-69*02 SCKASGGTF 
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HLA allele IGHV chain Peptide sequence HLA allele IGHV chain Peptide sequence 
HLA-B*0702 IGHV1-69 optim SCKASGGTF HLA-B*0702 IGHV1-69 optim WVRQAPGQG 
 IGHV1-69*03 SCKASGGTF  IGHV1-45*02 WVRQAPGQA 
 IGHV1-69*04 SCKASGGTF  IGHV1-3*01 WVRQAPGQR 
 IGHV1-69*05 SCKASGGTF  IGHV1-3*02 WVRQAPGQR 
 IGHV1-69*06 SCKASGGTF  IGHV1-24*01 WVRQAPGKG 
 IGHV1-69*08 SCKASGGTF  IGHV4-4*01 WVRQAPPQG 
 IGHV1-69*09 SCKASGGTF  IGHV4-4*02 WVRQAPPQG 
 IGHV1-69*10 SCKASGGTF  IGHV4-4*03 WVRQAPPQG 
 IGHV1-69*11 SCKASGGTF  IGHV4-4*04 WVRQAPPQG 
 IGHV1-69*12 SCKASGGTF  IGHV4-4*05 WVRQAPPQG 
 IGHV1-69*13 SCKASGGTF HLA-B*3501 IGHV1-69 optim IPIFGTANY 
HLA-B*0702 IGHV1-69 optim AISWVRQAP  IGHV1-69*01 IPIFGTANY 
 IGHV1-69*07 AISWVRQAP  IGHV1-69*03 IPIFGTANY 
  IGHV1-69*01  AISWVRQAP   IGHV1-69*05  IPIFGTANY 
 IGHV1-69*03 AISWVRQAP  IGHV1-69*06 IPIFGTANY 
 IGHV1-69*04 AISWVRQAP  IGHV1-69*07 IPIFGTANY 
 IGHV1-69*05 AISWVRQAP  IGHV1-69*12 IPIFGTANY 
 IGHV1-69*06 AISWVRQAP  IGHV1-69*13 IPIFGTANY 
 IGHV1-69*09 AISWVRQAP HLA-B*3501 IGHV1-69 optim TAYMELSSL 
 IGHV1-69*10 AISWVRQAP  IGHV1-24*01 TAYMELSSL 
 IGHV1-69*11 AISWVRQAP  IGHV1-3*01 TAYMELSSL 
 IGHV1-69*12 AISWVRQAP  IGHV1-3*02 TAYMELSSL 
 IGHV1-69*13 AISWVRQAP  IGHV1-45*01 TAYMELSSL 
 IGHV1-69*02 TISWVRQAP  IGHV1-45*02 TAYMELSSL 
 IGHV1-69*08 TISWVRQAP  IGHV1-45*03 TAYMELSSL 
 IGHV1-18*01 GISWVRQAP  IGHV1-58*01 TAYMELSSL 
 IGHV1-18*02 GISWVRQAP  IGHV1-58*02 TAYMELSSL 
HLA-B*0702 IGHV1-69 optim WVRQAPGQG  IGHV1-69*01 TAYMELSSL 
 IGHV1-69*07 WVRQAPGQG  IGHV1-69*02 TAYMELSSL 
 IGHV1-69*01 WVRQAPGQG  IGHV1-69*03 TAYMELSSL 
 IGHV1-69*02 WVRQAPGQG  IGHV1-69*04 TAYMELSSL 
 IGHV1-69*03 WVRQAPGQG  IGHV1-69*05 TAYMELSSL 
 IGHV1-69*04 WVRQAPGQG  IGHV1-69*06 TAYMELSSL 
 IGHV1-69*05 WVRQAPGQG  IGHV1-69*07 TAYMELSSL 
 IGHV1-69*06 WVRQAPGQG  IGHV1-69*08 TAYMELSSL 
 IGHV1-69*08 WVRQAPGQG  IGHV1-69*09 TAYMELSSL 
 IGHV1-69*09 WVRQAPGQG  IGHV1-69*10 TAYMELSSL 
 IGHV1-69*10 WVRQAPGQG  IGHV1-69*11 TAYMELSSL 
 IGHV1-69*11 WVRQAPGQG  IGHV1-69*12 TAYMELSSL 
 IGHV1-69*12 WVRQAPGQG  IGHV1-69*13 TAYMELSSL 
 IGHV1-69*13 WVRQAPGQG  IGHV1-2*01 TAYMELSRL 
 IGHV1-18*01 WVRQAPGQG  IGHV1-2*02 TAYMELSRL 
 IGHV1-18*02 WVRQAPGQG  IGHV1-2*03 TAYMELSRL 
 IGHV1-2*01 WVRQAPGQG  IGHV1-2*04 TAYMELSRL 
 IGHV1-2*02 WVRQAPGQG  IGHV1-46*01 TVYMELSSL 
 IGHV1-46*01 WVRQAPGQG  IGHV1-46*02 TVYMELSSL 
 IGHV1-46*02 WVRQAPGQG  IGHV1-46*03 TVYMELSSL 
 IGHV1-46*03 WVRQAPGQG  IGHV1-14*01 TAYMELSSQ 
 IGHV1-45*01 WVRQAPGQA    
Table 3. Sequence comparison of the optimized IGHV1-69 predicted epitopes with IGHV1-69 variants and 
sequences derived from Id proteins of the IGHV1 family. Optim is the abbreviation for optimized. Changes in the aa 
sequences are underlined. 
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Validation of the predicted epitopes 
Bioinformatics analysis of proteasomal cleavage in IGHV1-69 sequences 
The IGHV1-69 predicted epitopes were identified through a method based on their 
binding affinity to the HLA-allele molecules, but this system does not consider the natural 
processing of these peptides through the proteasomal machinery [115]. To further investigate 
this aspect, we analyzed the IGHV1-69 optimized sequence (Figure 10) and the germline 
sequence (data not shown) with the NETchop software and fixed at 0.5 (in order to maintain a 
good balance between the specificity and the sensitivity of the prediction) the threshold to 
detect a positive prediction, namely a cleavage of the downstream peptide bond following the 
aa residue. As shown in Figure 10, almost all (10 out of 13) of the predicted epitopes presented 
a high probability of proteasomal cleavage in at least one of the terminal aa residues (aa1 or 
aa9 of the sequence). HLA-A*2402-restricted GTF27-35, and HLA-B*0702-restricted SCK21-29 and 
AIS33-41 had low probability values in both aa1 and aa9, while HLA-A*0101-restricted epitopes 
seemed to have a high probability of proteasomal processing (i.e. positive prediction values in 
both the terminal residues).  
A.  
 
B. 
 
Figure 10. Graphical view of the proteasomal processing probability calculated for the IGHV1-69 optimized 
sequence and carried out with NETchop. The X axis represents the aa residues, while on Y axis are reported the 
predictions values. A cut-off of 0.5 was previously fixed to discriminate between positive and negative predictions. 
Epitopes are indicated with the first 3 aa residues of their sequence and colors characterized every HLA allele. A. 
HLA-A alleles: yellow –A*0101, green –A*0201, violet –A*0301, pink –A*2402. B. HLA-B alleles: blue –B*0702, 
brown –B*3501. 
RESULTS__________________________________________________________________ 
 50 
Flow cytometry analysis with ProVE
TM
 Pentamers 
To further validate the natural processing of predicted epitopes, we investigated the 
existence of epitope-specific CD8
+
 T cells through ProVE
TM
 Pentamers, which were synthesized 
for each predicted epitope of both the optimized and the patient-derived sequence. We first 
selected the most frequently expressed HLA alleles among the collected patients and decided 
to focus our attention on the HLA-A*0201, -A*0301, -A*2402 and -B*3501 specific pentamers. 
Moreover, to assess the possible background due to un-specific binding, we tested HLA-specific 
pentamers with PBMCs of HLA mismatched healthy donors (n=4). Figure 11 displays the 
adopted scheme of flow cytometric analysis, which was performed in the presence of α-CD4, α-
CD19 and α-CD8 to define the specific binding of these new reagents.  
 
 
Figure 11. Scheme of flow cytometry analysis performed to validate ProVE
TM
 Pentamers. α–CD19 and α–CD4 
antibodies were included to exclude un-specific binding signal. The staining was considered positive when the 
Mean Fluorescence Intensity (MFI) was >10
2
 in CD8
+
CD4
-
CD19
-
 cells (R7, calculated excluding CD19
+
 [R3] and CD4
+
 
[R2] cells). 
As shown in Table 4, the background signal in the HLA mismatched donors was generally 
very low, with the exception of pentamers SSN105-113 (HLA-A*2402) and DSS104-112 (HLA-B*3501) 
derived from the patient’s IGHV1-69, where the observed positivity was mainly due to an un-
specific binding to B cells. Interestingly, the specific positive signals were usually higher in 
samples obtained from patients (n=5) carrying IGHV1-69
+
 lymphoproliferation, than in HLA-
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matched healthy donors (n=6). Table 4 reports representative data obtained for some of the 
tested ProVE
TM
 pentamers. 
 
  HLA-mismatched donor HLA-matched donor Patient 
  % of pentamer
+
 cells on % of pentamer
+
 cells on % of pentamer
+
 cells on 
HLA-allele Peptide CD8
+ 
CD4
+
 CD19
+
 CD8
+ 
CD4
+
 CD19
+
 CD8
+ 
CD4
+
 CD19
+
 
-A*0201 FST32-40 0.06 0.00 0.00 0.05 0.01 0.10 0.12 0.01 0.06 
-A*0301 GSA18-26 0.02 0.00 0.17 0.07 0.01 0.06 0.10 0.00 0.05 
-A*2402 EWM46-54 0.03 0.02 0.19 0.02 0.03 0.09 0.28 0.08 0.18 
 SSN105-113 0.03 0.04 0.32 0.27 0.28 0.75 0.11 0.08 0.18 
-B*3501 IPI52-60 0.01 0.00 0.01 0.01 0.02 0.49 0.37 0.09 0.26 
 DSS104-112 0.14 0.12 0.59 0.03 0.04 0.56 0.84 0.22 1.08 
Table 4. Percentages of ProVE
TM
 pentamer-positive cells observed among CD8
+
, CD4
+
 and CD19
+
 lymphocytes in 
the peripheral blood of patients affected by a IGHV1-69
+
 lymphoproliferation, HLA-matched healthy donors, and 
healthy subjects with a different HLA-background. 
In view of the noticeable un-specific binding of pentamers obtained from the CDR3 
epitopes (SSN105-113, DSS104-112) identified in the patient’s IGHV1-69 sequence, we decided to 
focus further analyses only on the candidates identified in the IGHV1-69 optimized sequence. 
Identification and characterization of IGHV1-69 memory T-cell responses 
Ex vivo pentamer staining of patients and healthy donor PBMCs 
The validated epitope-specific pentamers were then tested ex vivo on PBMCs from 14 
patients carrying an IGHV1-69
+
 lymphoproliferation, 15 HLA-matched healthy donors, and 5 
healthy individuals with a different HLA background, in the context of HLA-A*0201, -A*2402 
and –B*3501 alleles (Figure 12A) (the HLA-A*0301-derived epitope was not evaluable in flow 
cytometry analyses because of the lack of a corresponding Pro5® pentamer. Experiments 
testing this epitope were carried out in IFN-γ ELISPOT assays and with the generation of 
epitope-specific T-cells). Overall, the pentamer
+
 percentage among CD8
+
 lymphocytes was 
significantly higher in patients (median=0.280; min-max 0.030-1.080) if compared with healthy 
donors expressing the same HLA alleles (median=0.095; min-max 0.015-0.650; p=0.014) (Figure 
12C). Moreover, both groups displayed higher numbers of pentamer-specific cells than HLA 
mismatched donors (median=0.009; min-max 0.002-0.060; p<0.001 compared to patients; 
p=0.002 compared to HLA matched donors) (Figure 12C), demonstrating the HLA-specificity of 
custom reagents. In parallel, the analysis with viral-specific pentamers (flu, CMV) revealed 
similar percentages of pentamer
+
 CD8
+
 lymphocytes between patients (n=10; median=0.170; 
min-max 0.040-1.720) and HLA-matched healthy donors (n=11; median=0.190; min-max 0.040-
4.080; p=0.817) (Figure 12B). This latter observation underlined and confirmed that in 
lymphoma patients we observed an exclusive prevalence of pentamer
+
 T-cells specific for the 
IGHV1-69 protein-derived epitopes.  
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A.       B. 
           
  C. 
 
Figure 12. Ex vivo IGHV1-69- and viral-specific pentamer staining on patients’ and healthy donors’ PBMCs. A. 
Examples of flow cytometry dot plots gated on living CD8
+
 lymphocytes. B. Graphical view of the global case study 
for virus-derived epitopes (patients n=10; healthy donors n=11). Every dot corresponds to the percentage detected 
in a single tested patient/donor for the specific pentamer. Percentages are calculated among living CD8
+
 
lymphocytes. Virus-derived epitopes are represented in the X axis with the first 3 aa residues: GIL is the HLA-
A*0201-restricted flu M158-66 peptide; QYD the HLA-A*2402-restricted CMV pp65341-349 peptide; IPS the HLA-
B*3501-restricted CMV pp65123-131 peptide. C. Graphical view of the global case study for IGHV1-69 specific 
epitopes (patients n=14; HLA-matched healthy donors n=15; HLA-mismatched healthy donors n=5). Epitopes are 
indicated in the X axis with the first 3 aa residues. Results were considered significant if p<0.05. 
Virus-derived  epitopes 
IGHV1-69 epitopes 
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Characterization of memory phenotype in IGHV1-69- and virus-specific CD8
+
 T cells 
Because of the different contribution of memory T cells subsets in mediating anti-tumor 
immune responses [105-107], the differentiation stage of pentamer
+
 CD8
+
 T cells was 
investigated through the combined analysis of the chemokine receptor CCR7 and the CD45RA 
isoform, to distinguish CCR7
+
CD45RA
+
 naïve (Tnaïve), CCR7
+
CD45RA
-
 central memory (TCM), CCR7
-
CD45RA
-
 effector memory (TEM), and CCR7
-
CD45RA
+
 terminally differentiated (TTemra) cells [108] 
(Figure 13A).  While healthy donors (n=9) displayed a higher frequency of TEM among virus 
specific CD8
+
 cells if compared to IGHV1-69-pentamer
+
 cells (55% versus 31.9%; p=0.03), no 
differences were highlighted in patients (n=10) pentamer
+
 cells when comparing the memory 
subsets between viral- and IGHV1-69-specific cells (TEM 38.5% versus 28.7%) (Figure 13B). 
Memory subsets in CD8
+
 T cells were not differently distributed between patients and healthy 
donors (Figure 13C). 
 
Figure 13. Characterization of the memory phenotype in pentamer
+
 CD8
+
 cells. A. Example of the flow cytometry 
gating strategy. B. Percentages of memory phenotype subsets in IGHV1-69
+
 cells and viral
+
 lymphocytes, measured 
in both healthy donors and patients. C. Percentages of memory phenotype subsets within the global CD8
+
 
population in patients and healthy donors. Results were considered significant if p<0.05. 
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Analysis of cytokine production by IGHV1-69-specific T cells 
To further characterize IGHV1-69-specific T cells, we investigated their functional status 
through the ability to produce cytokines after in vitro stimulation. In particular, we measured 
the production of IFN-γ in ELISPOT assays after stimulation with both IGHV1-69- and virus-
derived peptides in the context of HLA-A*0201, -A*0301, -A*2402, and -B*3501. Purified T 
lymphocytes isolated from patients (n=8) seemed to display a slightly higher number of IFN-γ 
secreting cells if stimulated with IGHV1-69-derived peptides as compared to viral-peptides 
stimulation (medianratio IGHV1-69 epitope/viral epitope=1.024; 0.399-3.600) (Figure 14). Moreover, the 
ratio between IGHV1-69-induced and viral-induced IFN-γ responses measured in patients’ T 
cells was significantly higher than the correspondent ratio obtained in healthy donors’ (n=8) 
purified T cells (medianratio IGHV1-69 epitope/viral epitope=0.700; 0.200-1.500; p=0.017) (Figure 14). 
These data were consistent with the higher prevalence of IGHV1-69-specific T cells (Figure 12) 
and the similar percentages of TEM between IGHV1-69- and viral-specific T cells observed in 
patients’ PBMCs (Figure 13B), if compared to the same analyses performed with healthy 
donors’ cells. 
 
Figure 14. IFN-γ responses induced after in vitro stimulation with IGHV1-69- and viral-derived peptides in patients’ 
and healthy donors’ PBMCs. Data are represented as the ratio between IGHV1-69- and viral-induced IFN-γ 
responses. Every dot represents the ratio measured for a single IGHV1-69 and viral peptide in each patient/healthy 
donor. IFN-γ responses are indicated as number of SFCs (spot forming cells). IGHV1-69 epitopes are represented in 
the X axis with the first 3 aa residues. Viral epitopes used as controls are: the HLA-A*0201-restricted flu M158-66 
peptide, the HLA-A*0301-restricted EBV EBNA3A-RLR603-611 peptide, the HLA-A*2402-restricted CMV pp65341-349 
peptide, and the HLA-B*3501-restricted CMV pp65123-131 peptide. Results were considered significant if p<0.05. 
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In vitro boosting of IGHV1-69-specific responses 
The in vitro immunogenicity of IGHV1-69-derived peptides was evaluated through their 
ability to induce epitope-specific CTLs from healthy donors’ and patients’ PBMCs, using 
different CTL generation protocols. 
Low IGHV1-69-specificity induced in healthy donors’ PBMCs 
IGHV1-69-derived peptides were used to induce CTLs by stimulating healthy donors 
PBMCs with peptide-pulsed autologous dendritic cells. After 5 stimulations, CTL cultures 
showed a specific, even if low, lytic activity against HLA-matched target cells loaded with the 
corresponding peptide, if compared to CTLs stimulated against known immunogenic peptides 
(MelanA/MART1 ELA26-35 for HLA-A*0201; CMV pp65 QYD341-349 for HLA-A*2402; CMV pp65 
IPS123-131 for HLA-B*3501) (Figure 15). We also tested the ability of CTL cultures to recognize a 
HLA-matched lymphoid B-cell line naturally expressing IGHV1-69. Interestingly, we observed 
some specific lysis, especially in 1 B*3501 donor, against the IGHV1-69+ PG B.95.8 cell line 
(HLA-A*0201; HLA-A*0301; HLA-B*3501) (Figure 15). 
 
 
Figure 15. Results of cytotoxicity assays performed with CTLs cultures generated from the PBMCs of 7 different 
healthy donors. Each color represents a single donor as indicated in the legend, which displays also the selected 
Effector:Target ratios. Tested peptides are indicated in the X axis with the first 3 aa residues and their source. 
Specificity was calculated subtracting to the lysis obtained in peptide-pulsed targets, the lysis measured in empty 
targets. The lysis against the IGHV1-69-expressing PG B.95.8 cell line (HLA-A*0201, -A*0301, -B*3501) was 
estimated incubating target cells also with the α–HLA class-I antibody w6/32. The difference between the lysis of 
the untreated- and the antibody-coated-cell line was considered as specific lysis. 
However, when compared to CTLs generated against positive controls, the pentamer 
staining of IGHV1-69-specific cultures was not clearly detectable (Figure 16), possibly due to the 
low affinity of the IGHV1-69-specific CTLs’ TCR to the pentamer, or to the low frequency of 
IGHV1-69-specific cells in the culture that justify the lower cytotoxicity observed in respect to 
ELA- or viral-specific CTLs (Figure 15).  
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Figure 16. Examples of dot plots achieved with pentamer staining of peptide-specific CTLs cultures obtained from 
healthy donors PBMCs. Graphs display the CD4
-
CD8
+
CD19
-
 population. Pentamer signalling was considered positive 
when mean fluorescence intensity > 10
2
, with the exception of CMV QYD341-349-specific pentamer that show a 
higher background. Peptide-specificity is indicated with the first 3 aa residues on the top of the correspondent dot 
plot (ELA is the HLA-A*0201-restricted MelanA/MART126-35 peptide; QYD the HLA-A*2402-restricted CMV pp65341-
349; QLV the HLA-A*0201-restricted IGHV1-693-11 peptide; EWM the HLA-A*2402-restricted IGHV1-6944-52 peptide).  
IGHV1-69-specific CTLs obtained from patient’s PBMCs displayed a higher specificity in cytotoxic 
assays than healthy donors’ derived CTLs cultures  
Considering the higher frequency of IGHV1-69-precursors observed in patients’ PBMCs 
(Figure 12C), we thought that it would be interesting to stimulate ex vivo patients IGHV1-69-
specific cells in order to obtain IGHV1-69 specific CTL cultures. We pulsed in parallel healthy 
donors’ (n=5) and patients’ (n=5) PBMCs with HLA-matched cell lines (T2-A2 for HLA-A*0201, 
C1R-A3 for HLA-A*0301) loaded with different concentrations of IGHV1-69-derived peptides 
(0.1μg/ml, 1μg/ml, or 10μg/ml) or with a positive control (5μg/ml). We first monitored the cell 
growth, and interestingly observed a higher rate of growth of patients’ cells if stimulated with 
IGHV1-69 peptides as compared to control stimuli, whereas in donors’ PBMCs the grater 
growth ratio was obtained with virus-derived peptides (Figure 17). 
RESULTS__________________________________________________________________ 
 57 
 
Figure 17. Cell count ratios in 4 exemplary CTLs cultures obtained from PBMCs of 2 patients and 2 healthy donors 
in the HLA-A*0201 and -A*0301 restrictions. Before each re-stimulation (T7 and T14), the number of cells was 
determined and divided for the starting amount of cells (T0).  
After 3 stimulations, we also characterized the CD8 and CD4 phenotype of CTLs cultures, 
and their memory differentiation status through a combined analysis of the surface markers 
CCR7 and CD45RA (Figure 18A) [108]. Within CTLs cultures derived from patients’ PBMCs, we 
interestingly observed an increase in the number of CD8
+
 T cells when a higher amount of 
IGHV1-69-peptide was used in the stimulations (between 0.1μg/ml and 10μg/ml, p=0.05) 
(Figure 18B). Moreover, we noticed that CTLs cultures generated against IGHV1-69 or viral 
peptides displayed a comparable proportion of CD8
+
 T cells and similar effector memory 
phenotype, if derived from both patients’ and healthy donors’ PBMCs (Figure 18B). 
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Figure 18. Phenotype characterization of CTL cultures derived from patients’ and healthy donors’ PBMCs. A. 
Examples of dot plots obtained gating live CD3
+
 lymphocytes (left column) and CD3
+
CD4
-
CD8
+
 cells (right column) 
in CTLs cultured obtained from one patient and one healthy donor. B. Summary of collected data regarding CTLs 
cultures generated from 4 patients and 4 healthy donors using 3 different concentration of IGHV1-69 peptide 
(0.1μg/ml, 1μg/ml, 10μg/ml) or a viral control (HLA-A*0201 restricted Flu M1-GIL58-66, and HLA-A*0301 restricted 
EBV EBNA3A-RLR603-611). TEM (Effector Memory) cells were identified as CCR7
-
CD45RA
-
, TTEMRA (Terminally 
differentiated) as CCR7
-
CD45RA
+
. Results were considered significant when p≤0.05. 
IGHV1-69-specific CTLs generated from PBMCs of 2 different patients revealed a 
detectable cytotoxicity against an HLA-matched cell line (T2-A2 for HLA-A*0201, and C1R-A3 for 
HLA-A*0301) pulsed with the specific peptide. Interestingly, IGHV1-69-specific cultures 
generated from 1 patient’s cells were able to kill more efficiently peptide-pulsed targets, if 
compared with the similarly-generated CTLs derived from healthy donor’s PBMCs (Figure 19A). 
Furthermore, in 8 CTLs cultures (4 from healthy donors’ and 4 from patients’ cells), we also 
measured a weak, but specific lysis, against the IGHV1-69
+
 PG B.95.8 cell line, with a more 
evident recognition by HLA-A*0301-restricted cultures (Figure 19B). 
Nevertheless, we were not able to observe a clear epitope-specific signal when testing 
these CTL cultures in flow cytometry with peptide-specific pentamers (data not shown). 
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Figure 19. Evaluation of CTLs specificity in cytotoxicity assays. A. Results obtained with CTLs cultures generated 
from the PBMCs of 2 different healthy donors and 2 patients in the HLA-A*0201 and –A*0301 restrictions. Peptide 
specificity is indicated along the X axis with the first 3 aa residues, the concentration used to load the APC, and the 
peptide source. Specific lysis was calculated as the subtraction between the value relating to the killing of empty 
targets, and the result obtained with peptide-pulsed targets. The Effector:Target ratio was 2.5:1. B. Lysis against 
the IGHV1-69-expressing PG B.95.8 cell line (HLA-A*0201, -A*0301, -B*3501). The specificity was estimated 
incubating target cells with the α–HLA class-I antibody w6/32. The difference between the lysis of the untreated- 
and the antibody-coated-cell line was considered as specific lysis. Patients’ and healthy donors’ origin, peptide-
specificity, and peptide concentration used to load APC are indicated along the X axis. The Effector:Target ratio 
was 10:1. 
Successful generation of IGHV1-69-epitope-specific CTLs cultures from healthy donor PBMCs 
using artificial APC 
At last, we tested a CTL generation protocol developed to boost low-avidity tumor-
directed T-cells [119] based on the use of artificial APC. After 3 stimulations, we successfully 
obtained IGHV1-69-epitope specific T-cells from CD8
+
 T cells of 1 healthy donor (#48), in the 
HLA-B*3501 restriction. These CTL cultures displayed a clear positivity in flow cytometry with a 
tetramer positive signal varying from 0.26% to 2.69% of CD8
+
 T cells (Figure 20). Parallel HLA-
A*0201 and -A*2402-restricted stimulations did not induce epitope-specific CD8
+
 T cells in this 
donor (data not shown). 
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Figure 20. Tetramer staining of CTL cultures obtained with aAPC stimulation of healthy donor CD8
+
 T cells. Dot 
plots on the left show the staining of CTLs cultures obtained with the negative control (DDX168-176, upper) and the 
positive control (EBV BRLF1109-117, lower) stimulation and stained with the corresponding tetramers and an α-CD8 
moAb. The right panel displays exemplary dot plots obtained after the staining of IGHV1-69 IPI50-58 stimulated CTLs 
cultures with IGHV1-69 HLA-B*3501 specific tetramer and an α-CD8 moAb. 
We finally isolate through immunomagnetic methods the IGHV1-69 IPI50-58 tetramer-
positive fraction of the CTLs cultures and clone it. Interestingly, after 1 month, we achieved the 
first T-cell clones, which resulted clearly positive in tetramer staining (Figure 21), even if, 
unfortunately, they did not display any cytokine release after peptide stimulation (data not 
shown). A more careful and deeper analysis of the obtained clones is ongoing. 
 
Figure 21. Tetramer staining of CTL clones obtained after immunomagnetic isolation of IGHV1-69-tetramer positive 
cells and stimulation with feeder cells every 2 weeks. Exemplary dot plots achieved with IGHV1-69 HLA-B*3501 
specific tetramer and α-CD8 moAb staining. All the graphs are gated on live lymphocytes. 
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DISCUSSION 
In this study we aimed at investigating the in vitro immunogenic features of the Id 
protein IGHV1-69, in order to establish its potential role as a suitable target for a shared 
immunotherapy against B-cell lymphomas/leukemias. The extreme heterogeneity of B-NHLs, 
together with their frequent resistance and relapses after chemo-radiotherapy and monoclonal 
antibodies, has made it difficult to develop a common therapy able to maintain the complete 
remission induced with standard treatments. In this field, in the last decades many efforts have 
been spent to investigate if Idiotype vaccines may represent the most suitable maintenance 
therapy, due to their high tumor-specificity and their low toxicity. However, despite 
encouraging results coming from phase I and II studies, 2 out of 3 phase III Id clinical trials failed 
to achieve the expected benefit in progression-free survival, thus abating the expectations 
placed in this type of vaccination. Several reasons have been ascribed to the failure of these 
trials, with particular attention to the study design and the selected endpoints. For example, 
the recruitment of both patients undergoing a complete response and those with a partial 
response after standard treatments resulted in a quite various population survey, which could 
be responsible for the different outcome after Id vaccination. Moreover, the lack of rituximab, 
currently used in the management of B-NHLs, in the pre-vaccination therapy of 2 clinical trials, 
did not allow to investigate the effect of B-cells depletion in the vaccination treatment. Finally, 
the choice of progression free survival as the major endpoint may be constrictive, and other 
evaluation criteria, as biological and clinical efficacy, should be considered. In our opinion, a 
more stringent definition of patients’ enrolment and the choice of suitable criteria of response 
to therapy, may overcome the current misses of Id vaccinations and enrich their potentialities. 
In this respect, the identification of a shared target for Id vaccines may facilitate the 
development of markers suitable for patient eligibility and response monitoring. Moreover, the 
selection of a common target could promote the design of an off-the-shelf Id vaccine, thus 
reappraising the present expensive and time-consuming production of patient-specific Id 
vaccines.  
Available data clearly indicate that IGHV1-69 is characterized by both tumor specificity 
issues and a shared expression among different B-NHL [28,30,57-61,71,77,81], thus combining 
the advantages of a reduced toxicity due to limited side effects, and decreased times and costs 
of production if compared to patient-tailored vaccines. In order to emphasize the properties of 
shared antigen, we designed an optimized IGHV1-69 sequence, conceived to enhance its 
similarity degree in respect to several IGHV1-69 sequences, obtained not only from different 
patients, but also in the context of various malignancies, while preserving or even enhancing 
immunogenicity. In this respect, the inclusion of a heterogeneous group of patients, affected by 
B-cell lymphoproliferations with different histological characteristics (Table 1), stresses the 
broad applicability of a therapeutic approach exploiting the features of IGHV1-69. In addition, 
the expression of this protein in pre-malignant lymphoproliferations evokes also a potential 
role of this target in preventive anti-tumor vaccination (Table 1) [58,60,77]. 
Sequence optimization was performed to further support the shared expression of the 
same aa variants among patients.  To do so, we excluded the hypervariable CDR3 region. In 
fact, even if this sequence’s portion is often a carrier of immunogenic epitopes [126], it is 
primarily responsible for sequence variability and thus involved in the individualized character 
of current Id vaccinations. Moreover, most of NHLs considered in this study, derived from 
antigen-experienced B cells, whose Id proteins may carry somatic mutations, especially in the 
CDR3 region, that could possibly affect immune recognition [56]. 
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When designing the optimized sequence we also took care of the most immunogenic 
regions using bioinformatics tools able to predict within a sequence the epitopes characterized 
by the highest binding affinity to selected MHC molecules [116-118]. The obtained sequence is 
thus optimized not only in the similarity degree among IGHV1-69 variants (Figure 9), but also in 
the preservation of immunogenic regions, which could at least in part overcome the low affinity 
to HLA molecules usually observed for self-antigen-derived epitopes, including Ig-derived 
peptides [64]. Indeed, one strategy to increase MHC binding and immunogenicity of low-
binding peptides is to modify the peptide at the MHC-binding aa residues while leaving the T-
cell–recognition residues intact [127]. The resultant “heteroclitic” peptides led to improved 
induction of CTL responses against melanoma in clinical trials [128], and interestingly also 
against IGV proteins in vitro [129]. Importantly, heteroclitic peptides elicited T-cell responses 
not only against the altered peptide but also against the native peptide from which they were 
derived. Moreover, they also intriguingly increased the killing efficacy of primary leukemic cells 
expressing the correspondent IGV protein and thus presumably the native peptide [129]. These 
observations suggest that MHC class I–restricted heteroclitic peptides can enlarge the pool of 
immunogenic peptides in B-cell malignant diseases and enhance the immunogenicity of these 
peptides [129]. In this context, we recently characterized the ability of IGKV3-20-specific CTLs to 
efficiently recognize and kill autologous targets presenting different A*0201-restricted IGKV3-
20 "variant" epitopes, often with a higher efficiency as compared with that elicited against the 
"native" epitopes [56]. Accordingly, these data strongly suggest that IGV proteins, in this case 
IGKV3-20, can be carriers of "natural" heteroclitic versions of several CTL epitopes shared by 
IGV proteins broadly expressed among lymphoid malignancies [56]. 
To definitively validate the most promising epitopes within the optimized IGHV1-69 
sequence, we did not restrict our self to the in silico analysis. We also investigated the ability of 
all possible IGHV1-69-derived nonamers to stabilize MHC complexes in the context of the 7 
most common HLA class-I alleles in the Caucasian population [122]. For this purpose, we used a 
novel technology able to measure the in vitro binding kinetics of T-cell epitopes to MHC 
molecules (ProImmune REVEAL & ProVE® Rapid Epitope Discovery System) [123,124]. It was 
interesting to observe that, through the HLA-binding affinity assay, the 13 predicted epitopes in 
the optimized sequence (Table 2) appear conserved or barely modified in several IGHV1-69 
variants, and surprisingly also in other proteins of the IGHV1 family or of molecularly related Id 
proteins (Table 3). This remark inspires a further extension of IGHV1-69-derived epitopes 
pertinence, even if a deeper analysis is needed to investigate the effects on IGHV1-69 
immunogenicity after heteroclitic peptide modifications. 
Nonetheless, the immunogenicity of a potential epitope depends also on the avidity of 
TCR binding to the peptide-MHC complex [114,125,130], which in turn should be investigated 
through the survey of epitope-specific T-cell responses in patients affected by 
lymphoproliferations expressing the relevant target. Presently, the results obtained so far 
support the existence of spontaneous T-cell memory-responses against IGHV1-69-derived 
epitopes in lymphoma patients, at least for some HLA restrictions (Figure 12). Therefore, the 
protein seems to be naturally processed and presented on MHC molecules, as further 
demonstrated by the ability of epitope-induced CTLs to specifically recognize an IGHV1-69
+
 cell 
line (Figures 15 and 19B). Moreover, the in silico analysis of proteasomal processing revealed 
that most of the predicted epitopes are potentially naturally produced (Figure 10), thus 
supporting the predicted immunogenicity of the identified epitopes [115].  
In addition, the ability to elicit HLA class I-restricted specific CTL responses ex vivo from 
different donors and patients (Figure 15, 19, and 20) rules out the possible existence of a 
central tolerance (against this Id protein) that could entail the lack of IGHV1-69-specific TCR 
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[131]. In this context, previous evidence supported the ability to generate, from healthy 
donors’ PBMCs, specific CTLs against epitopes shared by different proteins of the IGHV1 family, 
among whom we identified the IGHV1-69-derived QLV3-11 epitope [65]. With our analysis we 
further enforced this observation, demonstrating the capability of this epitope to induce 
specific CTLs also from patient’s PBMCs (Figure 19A). The common expression of the QLV3-11 
epitope in different IGHV proteins (Table 3) suggests that IGHV1-69-derived epitopes could 
potentially induce a cross-reactive response also against other molecularly related Id proteins, 
expressed in different lymphomas/leukemias. This prospective effect has already been 
described for IGKV3-20 protein, which was able to elicit cross-reactive responses against IGKV3-
20 proteins derived from different NHLs, and interestingly, also towards IGKV3-15, a related Id 
protein showing a 80% similarity degree with IGKV3-20 [56]. CTLs generated against IGKV3-20 
were able to efficiently recognize also IGKV3-20- and IGKV3-15-expressing lymphoma cells, in a 
HLA-A*0201-restricted manner [56]. On these grounds, the specific recognition that we 
observed against the IGHV1-69-expressing cell line with QLV3-11 stimulated CTL cultures (Figure 
15, and figure 19B), may assume a potential cross-reactive response induced by the optimized 
IGHV1-69 protein, against other IGHV1-69 proteins. The PG B.95.8 cell line in fact, expresses a 
variant IGHV1-69 sequence, which differ for some aa residues from the optimized sequence 
(80% homology between the 2 sequences), and could pave the way to a broader analysis of 
cross-reactive responses against other Id proteins of the IGHV1 family. 
To exclude the presence of peripheral tolerance mechanisms against IGHV1-69, we then 
searched for IGHV1-69 IFN-γ responses in lymphoma patients. Comparing the amount of IFN-γ 
release after peptide stimulation, we interestingly found that IGHV1-69-derived epitopes 
induced a higher response than known immunogenic epitopes do, only in lymphoma patients 
(Figure 14). These data are consistent with the increased number of IGHV1-69-specific T cells 
observed in lymphoma patients (Figure 12C), and with the similar memory phenotype between 
IGHV1-69- and virus- specific T cells documented in the same subjects (Figure 13), and further 
support the in vivo immunogenicity of this protein or at least of its derived epitopes. The almost 
evident higher response against IGHV1-69 epitopes observed ex vivo in patients’ cells, when 
compared to effects induced by viral epitopes, was further supported by the ability to stimulate 
in vitro epitope-specific CTLs more efficiently than viral-derived peptides (Figure 16, and figure 
18A pt#3). Withal, an increased dose of IGHV1-69 stimulating peptide enhanced the number of 
CD8
+
 T cells only within CTL cultures derived from patients’ PBMCs (Figure 17), thus underlying 
the stronger effect of IGHV1-69 stimulation in cells from lymphoma patients. Incidentally, the 
comparable memory phenotype observed in patients’ and healthy donors’ CTL cultures (Figure 
18), ruled out the possibility of an impairment of patients’ cells to differentiate into effector 
memory and terminally differentiated T cells. 
In this study, we mainly focused our attention on Id-derived epitopes, primarily because 
of the optimized character of IGHV1-69 sequence, which would require a dedicate production 
of the optimized protein. However, several papers demonstrated that peptides-based vaccines 
are often able to induce a more effective and specific response than the whole protein, maybe 
because they can elude the tolerance developed against the original protein [132-135]. 
Moreover, a recent paper proposed the use of Id-derived immunogenic peptides to selectively 
expand Id-specific T cells ex vivo and generate "educated" DLIs. Such primed T cells might 
enhance tumor specificity and limit Graft versus Host Disease complications of current DLI 
strategies [63]. For this purpose, a promising alternative is represented by the quite fast 
generation of epitope-specific T cells through artificial APC [119]. This strategy, in fact, allowed 
us to obtain an epitope-specific CTL population (Figure 20) in a shorter time if compared to 
traditional protocols, and to successfully generate a large number of epitope-positive clones 
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(Figure 21), which could be in turn expanded for DLI intentions, even if we still need to confirm 
their functionality. Furthermore, this approach does not require the production of autologous 
dendritic cells, which often represents the limiting step of TAA-specific CTLs generation and 
expansion. 
The early identification of immunogenic epitopes may also simplify the development of 
markers for patients’ eligibility and eventually therapy response. Indeed, multimers (tetramers 
and pentamers in this study) constitute a quick instrument to identify rare T cell populations, 
and to monitor their expansion during therapy, investigating their relationship with clinical 
response. Moreover, multimer staining offers many advantages over other T cell assays. In 
particular, this method is quantitative and fast, it is the only technique that allows an 
estimation of the avidity between TCR and peptide-loaded HLA molecules, and cells can be 
stained with additional markers simultaneously. An important issue of multimer utilization is 
that specific T cells can be analyzed regardless of their functional status including anergic or 
non-reactive T cells [92], thus requiring further techniques able to identify only functional T 
cells. For this reason, besides this method, other two assays are recommended as first-line 
monitoring tools in clinical vaccination studies: IFN-γ ELISPOT assays and intracellular cytokine 
staining (ICS) in flow cytometry [136]. IFN-γ ELISPOT owns the lowest detection limit for specific 
T cell responses at the single cell levels [137], while ICS allows the simultaneous analysis of 
multiple cytokines and phenotypic markers of T-cell activation, thus identifying multifunctional 
T cells [109,138]. These 3 assays, strongly suggested for the immune-monitoring of vaccination 
trials, require the early identification of the target of interest, and thus may benefit from 
previously identified epitopes. 
However, the lack of investigations on the whole IGHV1-69 protein represents a 
limitation of this study, and a crucial future step to definitively confirm the in vitro and in vivo 
immunogenicity of this protein. Another possible hindrance related to our study design may be 
the selection of a single chain Id protein, which causes the loss of the unique B-cell epitopes 
generated by the association of the variable portions of the heavy and light chains. 
Nevertheless, the choice of a single chain protein enlarges the potential targeted malignancies 
and the number of eligible patients. Moreover, we recently described that in a mouse model 
repeated immunizations with the single chain Id protein IGKV3-20 boosted detectable levels of 
Ig capable of recognizing naturally folded, public epitopes physiologically present on the 
membrane-mounted protein [56]. For this reason, we speculate that the same effect could be 
obtained also with other single chain Id proteins, as IGHV1-69. Finally, the selection of a self 
antigen, which is also expressed in a small proportion of normal B cells, may cause the deletion 
of IGHV1-69
+
 normal B cells [78-80]. Available evidence, however, indicate that Id vaccines, 
which include both heavy and light chains, are safe and associated with only modest toxic 
effects, with no evidence of immune compromise related to depletion of part of B-cell 
repertoire [56]. 
Hence, the data presented in this study support the in vitro immunogenicity of IGHV1-
69-derived epitopes, and pave the way to further in vivo pre-clinical experiments aimed at 
definitively confirm the IGHV1-69 ability to induce an immune response, which could be able to 
restrain tumor growth in vivo. Moreover, we intend to design and prepare viral vectors allowing 
the expression of the optimized IGHV1-69 sequence fused to an enhancer of the immune 
response, as mycobacterium tubercolosis heat shock protein 70, in order to develop an IGHV1-
69-targeting DNA vaccination, which could extend the application of this approach. 
 
In conclusion, the results of the present study indicate that IGHV1-69 constitutes an 
attractive target candidate for the development of a subset-specific idiotypic vaccine, 
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potentially addressed to the 40% of patients affected by an HCV-associated lymphoma, the 13% 
of CLL patients, and almost the 70% of patients with an autoimmunity-related B-cell 
lymphoproliferation. Furthermore, multimers and ELISPOT-based immune-assays may be 
particularly useful to select patients who could be eligible for the IGHV1-69-based vaccination 
and to identify those showing specific T-cell responses. Accordingly, improved selection of 
eligible patients and a more precise monitoring of specific immune responses may further 
improve the clinical efficacy of “shared Id” vaccines in the maintenance of a complete response 
after standard therapy in B-NHL patients. 
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APPENDIX 
Healthy donor 
number 
HLA class I 
genotyping 
Healthy donor 
number 
HLA class I 
genotyping 
Healthy donor 
number 
HLA class I 
genotyping 
#1 negative for 
interested alleles 
#18 -A*2402 #35 -A*0201 
#2 -A*2402 #19 negative for 
interested alleles 
#36 -A*0101, -A*0201 
#3 -B*3501 #20 -A*2402 #37 -A*0201 
#4 negative for 
interested alleles 
#21 -A*2402 #38 -A*0301, -A*2402 
#5 -B*0702 #22 -A*0201 #39 -A*0201 
#6 -A*0201 #23 -A*0201 #40 -A*0301 
#7 -A*0301 #24 -A*2402 #41 -A*0201, -B*3501 
#8 -A*0201 #25 -B*3501 #42 -A*0301, -A*2402 
#9 -A*0301 #26 -B*3501 #43 -A*0201, -A*2402 
#10 -B*0702 #27 -A*0201 #44 -B*3501 
#11 -A*0301, -A*2402 #28 -A*0201 #45 -A*0201 
#12 -A*0301 #29 -A*2402 #46 -A*2402 
#13 -A*2402 #30 -A*2402 #47 -B*3501 
#14 -A*0301 #31 -A*0301 #48 -A*0201, -A*2402, -
B*3501 
#15 -A*0101, -A*0201 #32 -A*2402 #49 -A*0201 
#16 -A*0101 #33 -A*0201, -B*3501 #50 -A*0301, -A*2402 
#17 -A*0201, A*0301 #34 -A*0201, -B*3501 #51 -A*0201 
Table 5. HLA genotyping of healthy donors collected for the study. 
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